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1. Introduction 
1.1. Progenitor/stem cells in the adult mouse lung 
The adult mouse lung consists of at least 40-60 different types of cells that are 
organized in a highly sophisticated 3D structure inside the thoracic cavity 
(Crapo et al., 1982; McQualter and Bertoncello, 2012). This complexity is 
necessary in order to carry out gas exchange between the blood stream and 
the external environment and thus maintain body homeostasis. These cell 
types can be broadly classified into epithelial cells (populating the airways) 
and mesenchymal cells (populating the surrounding extracellular matrix). 
From an anatomical point of view, the mouse lung can be divided into a 
proximal and distal region (Fig. 1). The proximal region consists of the trachea 
and mainstem bronchi and is distinguished by its pseudostratified epithelium 
and the presence of cartilageous rings. This region is populated by basal 
cells, goblet cells, neuroendocrine cells, ciliated cells and non-ciliated 
secretory cells (or Clara cells). On the other hand, the distal region is 
characterized by its columnar epithelium and the absence of basal cells or 
cartilageous tissue. This region contains few goblet cells and in addition to 
ciliated and secretory cells, type I and type II alveolar epithelial cells (AEC 
I/II). AEC I are squamous epithelial cells that occupy around 95% of the 
alveolar space and are responsible for gas exchange. AEC II are cuboidal 
epithelial cells and they produce surfactants that maintain a low surface 
tension in the alveolar space and prevent the alveoli from collapsing 
[Reviewed in (Rawlins and Hogan, 2006; Rock et al., 2010; Rock and Hogan, 
2011; McQualter and Bertoncello, 2012)]. 
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Figure 1. Schematic representation of the postnatal mouse lung showing the 
different cell types along the proximodistal axis. 
Note that cartilage rings do not extend beyond mainstem bronchi in mice while in 
humans, they are found deep within the lung. Abbreviations: AEC I: Type I alveolar 
epithelial cell; AEC II: Type II alveolar epithelial cell; Alv: Alveolus; BADJ: 
Bronchoalveolar duct junction; BASC: Bronchoalveolar stem cell; Br: Bronchus; Brl: 
Bronchiole; ECM: Extracellular matrix; NEB: Neuroepithelial body (containing 
neuroendocrine cells); PBSMC: Parabronchial smooth muscle cell; Tr: Trachea. 
Adopted and modified from (Rawlins and Hogan, 2006; Rock et al., 2010; Rock and 
Hogan, 2011; Garcia et al., 2012; McQualter and Bertoncello, 2012). 
 
Introduction                                                                                                     3 
 
Along the proximodistal axis, the mouse lung is rich with stem/progenitor cells 
that are capable of self-renewal, multipotent differentiation and pollutant 
resistance. In this section, the different types of lung progenitor/stem cells will 
be reviewed. 
1.1.1. Epithelial stem cells and their niches in the adult mouse lung 
The adult lung epithelium has a remarkably low cell-turnover rate (Rawlins 
and Hogan, 2008). However, many injury models have been devised to 
selectively target various cell types in the lung epithelium. Upon injury, 
progenitor/stem cells located in certain microenvironments (niches) undergo 
rounds of proliferation and differentiation to ensure epithelial regeneration. 
Most of our knowledge regarding the lineage tree of epithelial cells derives 
from ex vivo studies (eg. rat tracheal xenograft model) (Shimizu et al., 1992), 
in vitro cell cultures and epithelial regeneration after injury. The latter includes 
the naphthalene injury model (to study regeneration of Clara cells), injury by 
inhalation of oxidants such as NO2/Ozone and Oxygen (to study regeneration 
of ciliated and AEC I respectively) and injury by inhalation of SO2 (to study 
regeneration of multiple epithelial lineages). These experimental approaches 
are reviewed in (Rawlins and Hogan, 2006). 
Using the aforementioned approaches, it has been shown that in the upper (or 
proximal) airways, there are at least three distinct populations of epithelial 
progenitors. These include basal cells (Krt5+; Krt14+) (Hong et al., 2004; 
Schoch et al., 2004; Rock et al., 2009) and variant Clara cells (Scgb1a1+; 
Cyp2f2-) within neuroepithelial bodies (as progenitors for ciliated and 
secretory cells) (Stripp et al., 1995) as well as Submuscosal gland (SMG) duct 
cells (Krt5+; Krt14+) (as progenitors for the tracheal epithelium) (Borthwick et 
al., 2001). As for the lower (or distal) airways, variant Clara cells at the 
Bronchoalveolar duct junctions (BADJs) (Scgb1a1+; Sftpc+; Cyp2f2-) have 
been suggested as stem cells (termed BASCs for Bronchoalveolar stem cells) 
as they are capable of regenerating bronchiolar Clara cells as well as alveolar 
cells (Giangreco et al., 2002; Kim et al., 2005). Moreover, AEC II (Sftpc+) have 
been shown to be progenitors for AEC I (Aqp5+) (Adamson and Bowden, 
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1974; Evans et al., 1975; Rock et al., 2011). These findings are summarized 
in Table 1. 
Table 1. Epithelial progenitors in the adult mouse lung. 
Distinct types of epithelial progenitors populate the adult mouse lung along the 
proximodistal axis. SMG duct cells, basal cells and variant Clara cells within NEBs 
populate the upper airways whereas variant Clara cells at BADJs and AEC II 
populate the distal airways. Abbreviations: Cyp2f2: Cytochrome P4502F2; Krt5: 
Cytokeratin-5; Krt14: Cytokeratin-14; Scgb1a1: Secretoglobin, family 1A, member 
1; Sftpc: Surfactant protein C; SMGs: Submucosal glands. Reviewed in (Garcia et 
al., 2012). 
 
Progenitor / 
stem cells 
Markers Progeny Experimental model 
Proximal airways 
SMG duct 
cells of the 
upper trachea 
Krt5+; 
Krt14+ 
Tracheal epithelium Rat tracheal xenograft 
Basal cells in 
trachea and 
main bronchi 
Krt5+; 
Krt14+ 
Ciliated and 
secretory cells 
Rat tracheal 
xenograft/SO2 
inhalation/Naphthalene 
injury 
Variant Clara 
cells within 
NEBs 
Scgb1a1+; 
Cyp2f2- 
Ciliated and 
secretory cells 
Naphthalene injury 
Distal airways 
Variant Clara 
cells at BADJs 
(putative 
BASCs) 
Scgb1a1+; 
Sftpc+; 
Cyp2f2- 
Bronchiolar  
and alveolar cells 
Naphthalene 
injury/Bleomycin injury 
AEC II Sftpc+ AEC I O2/NO2/Bleomycin 
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In a similar context, Kim et al. have identified BASCs as CD45- CD31- Sca-1+ 
CD34+ cells. These cells showed resistance to bronchiolar and alveolar 
damage and proliferated during epithelial regeneration following injury. These 
cells represent 0.008-0.064% of the total F1 129/SvJ/C57BL/6 adult lung (Kim 
et al., 2005). On the other hand, McQualter et al. were able to define lung 
epithelial stem/progenitor cells as EpCamhi CD49f+ CD104+ CD24low. Their 
study was based on the ability of this cell population to form colonies in the 
presence of mesenchymal support, giving rise to airway, alveolar and mixed 
epithelial lineages. These epithelial stem/progenitor cells constitute less than 
0.02% of the total C57BL/6 adult lung (McQualter et al., 2010). This work was 
complemented by Chapman et al. who used the bleomycin injury model to 
demonstrate that Sftpc- CD49f+ CD104+ cells constitute a stable progenitor 
population that replenishes AEC II during lung repair (Chapman et al., 2011). 
The various cluster of differentiation (CD) molecules used to define 
progenitor/stem cell populations are summarized in Supplementary Table S1. 
1.1.2. Mesenchymal stromal (stem) cells (MSCs) in the adult mouse lung 
Contrary to the lung epithelium, the lineage tree of the lung mesenchyme is 
poorly understood. This part of the lung consists of a wide array of cell types 
such as smooth muscle cells, endothelial cells, chondrocytes, nerve cells, 
lipofibroblasts, myofibroblasts, lymphatic cells and others. Whereas epithelial 
progenitors have been identified using the aforementioned epithelial injury 
models, very little success has been made in understanding the hierarchy, if 
any, of mesenchymal progenitors in the adult mouse lung. Models of fibroblast 
hyper-proliferative diseases such as asthma, pulmonary arterial hypertension 
(PAH) and lung fibrosis have been routinely used and many hypotheses have 
been suggested regarding the origin of over-proliferating fibroblasts. For 
instance, the origin of collagen-secreting, αSma-positive activated 
myofibroblasts in lung fibrosis is still unknown. It is believed that they originate 
from resident fibroblasts (Phan, 2002; Hoyles et al., 2011), bone marrow-
derived circulating fibrocytes (Phillips et al., 2004; Lama and Phan, 2006) or 
AEC II via epithelial-to-mesenchymal transition (EMT) (Grunert et al., 2003; 
Kim et al., 2006). However, due to the lack of cell-specific markers, these 
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hypotheses remain controversial. Rock et al. have recently demonstrated that 
stromal cells, in bleomycin-induced pulmonary fibrosis in mice, exhibit 
heterogeneity and that pericyte-like cells undergo proliferation but fail to 
express high levels of the myofibroblast marker (αSma). The authors also 
used a SftpcCre-ERT2 knock-in line to demonstrate the absence of EMT by AEC 
II (Rock et al., 2011). 
Despite our poor knowledge regarding mesenchymal hierarchy in the lung, 
many studies have reported the presence of mesenchymal stromal (stem) 
cells (MSCs) in adult mouse lungs as well as fetal human lungs (Pittenger et 
al., 2000; Sabatini et al., 2005; Summer et al., 2007). These cells have the 
ability to commit to multiple fates including chondrogenic, adipogenic and 
myogenic lineages. Isolation and characterization of murine lung stem cells is 
based on their ability to efflux Hoechst 33342 dye and expression of Stem cell 
antigen 1 (Sca-1) and Mast/stem cell growth factor receptor Kit (c-Kit). Cells 
that have the preference to efflux Hoechst 33342 dye are referred to as Side 
population (SP) cells and they can be further categorized as having 
hematopoietic (CD45+) or non-hematopoietic (CD45-) origins (Goodell et al., 
1996; Giangreco et al., 2004). CD45- CD31- Sca-1+ CD34+ SP cells were 
found to highly express stem cell markers such as Sca-1 as well as markers 
specific to mesenchymal lineages such as Thymocyte antigen 1 (Thy-1) and 
Platelet-derived growth factor receptor alpha (Pdgfrα). This population of cells 
is referred to as resident MSCs and accounts for approximately 1% of the 
total C57BL/6 adult lung (McQualter et al., 2009) (Fig. 2). 
 
 
Introduction                                                                                                     7 
 
 
 
Figure 2. Scheme for the isolation strategy of resident MSCs from the adult 
mouse lung. 
Cell suspensions from adult mouse lungs can be divided into SP and non-SP based 
on their ability to retain Hoechst dye. McQualter et al. have demonstrated that 
CD45- CD31- Sca-1+ CD34+ SP cells represent a population of resident progenitor 
cells and express mesenchymal-specific markers such as Thy-1 and Pdgfrα. 
Abbreviations: MSCs: Mesenchymal stromal (stem) cells; SP: Side population. 
In a similar context, Volckaert et al. have demonstrated that parabronchial 
smooth muscle cells (PBSMCs) represent a mesenchymal stem cell niche 
that is critical for epithelial regeneration following naphthalene injury. Their 
data suggest that Fgf10 expression by PBSMCs is required for epithelial 
repair by variant Clara cells (Volckaert et al., 2011). 
1.2. Overview of lung development: Progenitor cells are 
enriched in the embryonic lung 
During murine embryonic development, the respiratory tract starts to form at 
embryonic day 9.5 (E9.5) as a budding of the ventral foregut endoderm. This 
respiratory domain is marked by Thyroid transcription factor 1 (Ttf-1 or 
Nkx2.1) expression. Around one day later (E10.5), the two lung buds are 
formed. At this stage, the splanchnic mesoderm sends instructive signals to 
the endoderm-derived epithelium to undergo branching morphogenesis 
(Spooner and Wessells, 1970). This developmental stage, termed 
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‘Pseudoglandular stage’, lasts until E16.5 (Fig. 3). The currently accepted 
branching model for the embryonic mouse lung consists of domain branching, 
planar bifurcation and orthogonal bifurcation (Metzger et al., 2008). In the 
meantime, many of the cell types that will populate the lung later on start to 
emerge. These include basal, neuroendocrine, ciliated and secretory cells. 
The lung then undergoes a short canalicular stage (E16.5 to E17.5) that is 
characterized by the formation of blood capillaries. During this stage, AEC I 
and II start to appear. In mice, functional alveoli start to form postnatally (from 
postnatal day 5 up to one month of age) whereas in humans, this process 
starts during late gestation and lasts up to two years. The alveolar stage is 
characterized by secondary septa formation and microvascular maturation 
(Burri, 2006). Reviews on lung development include (Cardoso, 2000; 
Warburton et al., 2000; Affolter et al., 2003; Cardoso and Lu, 2006; Morrisey 
and Hogan, 2010). 
 
 
Figure 3. Overview of murine lung development showing the main events and 
arising cell types according to their chronological order. 
NE: Neuroendocrine. 
During the time course of lung development, proximal-distal patterning arises 
from a complex network of signaling pathways that control the proliferation, 
migration and differentiation of progenitor cells. In this section, epithelial and 
mesenchymal progenitors will be reviewed, with special emphasis on the role 
of paracrine interactions in specifying cell fate in the embryonic lung. 
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1.2.1. Epithelial progenitors are located at the distal tips in the 
embryonic lung 
One of the early attempts to establish an epithelial progenitor cell hierarchy in 
the embryonic lung was done by Wuenschell et al. who used an 
immunohistochemical approach to demonstrate the spatio-temporal 
expression of epithelial markers during development (Wuenschell et al., 
1996). The authors used Calcitonin gene-related peptide (Cgrp), Clara cell 
secretory protein (Ccsp or Scgb1a1) and Surfactant protein-A (Sftpa) as 
markers of differentiated neuroendocrine cells, Clara cells and AEC II 
respectively. The authors concluded that all three markers are co-expressed 
in the distal epithelium between E13 and E15, after which they are restricted 
to specific cell lineages. The data suggest that most epithelial lineages are 
derived from common progenitors from the pseudoglandular stage. 
On the other hand, Perl et al. used transgenic mice carrying (rat) Ccsp-rtTA or 
(human) SFTPC-rtTA; Tet(O)-Cre constructs combined with Alkaline 
phosphatase or GFP reporters to demonstrate that ciliated and non-ciliated 
cells, but not neuroendocrine cells, derive from common Scgb1a1+ Sftpc+ 
progenitors (Perl et al., 2005). 
More recently, Rawlins et al. used an Inhibitor of differentiation 2 knock-in 
mouse line (Id2Cre-ERT2) to target epithelial progenitors during the 
pseudoglandular and canalicular stages of lung development (Rawlins et al., 
2009). Their data show that Id2-positive progenitor cells, located in the distal 
tips of the lung epithelium, give rise to ciliated, non-ciliated and 
neuroendocrine cells when labeled at the pseudoglandular stage. In contrast, 
these cells only contribute to alveolar cells when labeled at the canalicular 
stage. Lastly, the Id2-positive progenitor cell population is not retained after 
birth. 
In this context, Notch signaling pathway has been proposed to be critical for 
establishing a balance between ciliated and non-ciliated cell fates in the 
developing lung. Conditional inactivation of Notch signaling in the endoderm 
using ShhCre leads to the enrichment of ciliated cells at the expense of non-
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ciliated secretory cells (Tsao et al., 2009). Moreover, members of the 
Forkhead box protein family have also been proposed to be involved in 
specifying cell fate and controlling proliferation rates of epithelial progenitors. 
Recently, it has been shown that FOXP1 and 4 transcription factors act during 
development to repress the Goblet cell program in epithelial progenitors (Li et 
al., 2012). 
Wnt signaling has been shown to play an important role in proximal-distal 
patterning of the developing lung epithelium. Loss of function of β-Catenin 
using SFTPC-rtTA; Tet(O)-Cre system leads to the inhibition of distal airways 
and enlargement of the proximal airways (Mucenski et al., 2003). An opposite 
phenotype was reported with gain of function of β-Catenin using Ccsp-rtTA; 
Tet(O)-Cre system (Mucenski et al., 2005). 
To sum up, distal epithelial progenitors, having a high proliferation index and 
expressing Sox9 and Id2, give rise to most of the epithelial cell types during 
the pseudoglandular stage. As these cells lose Sox9 and Id2 expression and 
start expressing the proximal lung marker Sox2, their lineage commitment 
becomes restricted to specific cell types. Notch, Wnt, BMP and FGF signaling 
pathways are believed to be involved in fate determination of epithelial 
progenitors during lung development [Reviewed in (Rock and Hogan, 2011)]. 
1.2.2. Mesenchymal progenitor cells in the developing mouse lung 
The lung mesenchyme consists of a widely heterogeneous population of cells 
that play crucial roles during development and homeostasis after birth. Some 
of these cell types derive from a common multipotent mesenchymal 
progenitor whereas others derive from a unique progenitor population. A 
number of mesenchymal progenitors have been identified using transgenic 
and knock-in mouse lines that allow fate mapping of mesenchymal cells 
during lung development. For example, our research group has previously 
used Fibroblast growth factor 10 (Fgf10)-LacZ transgenic line (originally 
reported as Mlcv1v-nLacZ-24) to demonstrate that Fgf10-expressing cells are 
progenitors for PBSMCs in the distal lung during early embryonic 
development (Mailleux et al., 2005). Shan et al., on the other hand, have 
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identified a population of mesenchymal cells, initially located near the lung 
hilum, as progenitors for airway smooth muscle cells (Shan et al., 2008). 
Using Wilm's tumor protein 1 (Wt1)-Cre transgenic line, Que et al. have 
suggested that the mesothelium is a source of vascular – but not airway – 
smooth muscle cells (Que et al., 2008). On the contrary, Greif et al. have 
shown that vascular smooth muscle cells arise from Pdgfrβ-positive 
mesenchymal cells rather than Wt1-positive mesothelial cells (Greif et al., 
2012). Fetal liver kinase 1 (Flk-1), another term for Vascular endothelial 
growth factor receptor 2 (Vegfr2), has been identified as the earliest marker 
for endothelial progenitors (angioblasts). These cells respond to epithelial as 
well as mesenchymal VEGF-A, and give rise to the capillary plexus 
surrounding the airways. Flk-1-positive endothelial progenitors were identified 
using Flk-1-LacZ transgenic mice (Yamaguchi et al., 1993; Kappel et al., 
1999; Del Moral et al., 2006). Hematopoietic cells were shown to also derive 
from Flk-1-positive cells in the lung (Lugus et al., 2009). Using Prospero 
homeobox protein 1 (Prox1)Cre-ERT2 knock-in line, Srinivasan et al. have shown 
that lympthatic cells arise from Prox1-positive progenitor cells (Srinivasan et 
al., 2007). On the hand, Langsdorf et al. have shown that nerve cells originate 
from the neural crest. The authors used Receptor tyrosine kinase (Ret)eGFP 
knock-in line to transiently trace neuronal progenitors during embryonic 
development (Langsdorf et al., 2011). Table 2 shows some of the different 
mesenchymal cell types and their progenitors as well as the developmental 
stage at which they start to appear in the lung. 
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Table 2. Mesenchymal cell types, the stage at which they start to emerge and 
their corresponding progenitors in the embryonic and postnatal mouse lung. 
Abbreviations: Flk-1: Fetal liver kinase 1 (or Vegfr2); LECs: Lymphatic endothelial 
cells; NCCs: Neural crest-derived cells; Pdgfrα/β: Platelet-derived growth factor 
receptor alpha/beta; Prox1: Prospero homeobox protein 1; Ret: Receptor tyrosine 
kinase; Wt1: Wilm’s tumor protein 1. 
 
Mesenchymal cell 
type 
Time of 
onset 
Progenitor 
cells 
Reference(s) 
Endothelial cells E9.5 Flk-1+ cells 
(Yamaguchi et al., 1993; 
Kappel et al., 1999) 
Hematopoietic 
cells 
E9.5 Flk-1+ cells (Lugus et al., 2009) 
Lymphatic cells E9.5 Prox1+ LECs (Srinivasan et al., 2007) 
Nerve cells E11.5 Ret+ NCCs (Langsdorf et al., 2011) 
Parabronchial 
smooth muscle 
cells 
E11.5 Fgf10+ cells 
(Mailleux et al., 2005) and 
(El Agha et al., in revision) 
Vascular smooth 
muscle cells 
E11.5 
Wt1+ cells (Que et al., 2008) 
Pdgfrβ+ cells (Greif et al., 2012) 
Fgf10+ cells (El Agha et al., in revision) 
Cartilage 
E13.5-
E15.5 
Unknown (Miller et al., 2004) 
Lipofibroblasts E15.5 Fgf10+ cells (El Agha et al., in revision) 
Alveolar 
myofibroblasts 
P4 Pdgfrα+ cells 
(Boström et al., 1996; 
Lindahl et al., 1997) 
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Most of the aforementioned mesenchymal lineages start to emerge during 
early stages of lung development (Table 2). In mice, the last stage of lung 
development occurs postnatally and is characterized by the transition from 
primitive alveoli (sacs) to mature alveoli (Fig. 3). This stage is characterized 
by the prevalence of two mesenchymal lineages: Alveolar myofibroblasts and 
lipofibroblasts. Alveolar myofibroblasts represent a population of αSma-
positive interstitial fibroblasts that populate the lung during postnatal 
alveolarization. These cells deposit ECM proteins that are critical for 
secondary septa formation (Vaccaro and Brody, 1978; Noguchi et al., 1989; 
Yamada et al., 2005) and are believed to derive from Pdgfrα-positive cells. 
Platelet-derived growth factor a (Pdgfa)-null newborns suffer from arrest in 
alveologenesis due to the absence of alveolar myofibroblasts (Boström et al., 
1996; Lindahl et al., 1997). 
On the other hand, the origin of lipofibroblasts is poorly understood. 
Lipofibroblasts are adipocyte-like interstitial fibroblasts that reside in the late 
fetal and postnatal lung parenchyma in the vicinity of AEC II (O’Hare and 
Sheridan, 1970; Vaccaro and Brody, 1978). AEC II signal to lipofibroblasts via 
Parathyroid hormone-related protein (PTHrP) to activate the Peroxisome 
proliferator-activated receptor gamma (PPARγ) pathway. This signaling 
pathway has shown to be critical for the induction and maintenance of the 
lipofibroblast phenotype. In vivo inactivation of the PTHrP pathway leads to 
abnormal alveolarization with defective surfactant synthesis (Rubin et al., 
2004; Torday and Rehan, 2007; Rehan and Torday, 2012). In response to 
PPARγ activation, lipofibroblasts express Adipose differentiation-related 
protein (Adrp) that is critical for trafficking of lipid substrates and subsequently 
providing AEC II with triglycerides for surfactant production (Schultz et al., 
2002). Lipofibroblasts also secrete leptin that stimulates surfactant production 
by AEC II (Torday et al., 2002) (Fig. 4). In addition to triglycerides, 
lipofibroblasts also store retinoic acids which are essential for alveolar 
septation (Simon and Mariani, 2007). 
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Figure 4. Schematic representation of lipofibroblast-AEC II interactions. 
AEC II signal to lipofibroblast progenitors via PTHrP to induce and maintain the 
lipofibroblast phenotype and prevent their transdifferentiation to activated 
myofibroblasts. In response to PTHrP, PPARγ pathway is activated, resulting in 
Adrp and Leptin expression. Lipofibroblasts provide AEC II with triglycerides for 
surfactant production. It has been proposed that injury to AEC II leads to 
downregulation of PTHrP leading to lipofibroblast-to-myofibroblast 
transdifferentiation. Abbreviations: Adrp: Adipose differentiation-related protein; 
PPARγ: Peroxisome proliferator-activated receptor gamma; PTHrP: Parathyroid 
hormone-related protein. 
In summary, lipofibroblasts are believed to be critical not only for surfactant 
production but also for alveolar septation. It has been demonstrated that injury 
to AEC II, caused by prematurity, barotrauma, hyperoxia, nicotine or 
infections, disrupts paracrine PTHrP signaling leading to lipofibroblast-to-
myofibroblast transdifferentiation (Torday et al., 2003) (Fig. 4). This scenario 
is likely to occur in idiopathic pulmonary fibrosis (IPF) especially that it has 
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been shown that lipofibroblasts exist in adult human lungs (Rehan et al., 
2006). In this dissertation, we provide evidence that Fgf10-expressing cells 
are progenitors for lipofibroblasts in the embryonic as well as postnatal lung. 
The simplest developmental stage that allows studying of paracrine signaling 
pathways in the embryonic lung is the mid-pseudoglandular stage (around 
E13.5). At this stage, it is easy to distinguish the three layers that constitute 
the lung: the mesothelium that constitutes the outer-most layer, the 
mesenchyme that constitutes the ECM and the epithelium which is the inner-
most layer. The mesenchyme can be further divided into two compartments, 
each of which is populated by distinct mesenchymal progenitors: the dense 
circumferentially-oriented sub-epithelial mesenchyme (SEM) and the rather 
loose non-oriented sub-mesothelial mesenchyme (SMM) (White et al., 2006) 
(Fig. 5A). It is widely accepted that the interaction between these multiple 
cellular domains is critical for amplification of progenitors as well as cell-fate 
determination. Tissue interactions and their role in lineage commitment of 
mesenchymal cells will be discussed in the following section. 
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Figure 5. Tissue interactions and mesenchymal cell-fate determination in the 
embryonic lung. 
(A) Schematic representation showing the different cellular layers as well as 
mesenchymal and mesothelial progenitor cells in the embryonic mouse lung at 
E13.5. The lung epithelium is lined by PBSMCs (violet) from the proximal side. The 
smooth muscle cell layer is innervated by neural crest-derived Ret-positive cells 
(pink). The latter cells exist in the form of neuronal fibers (surrounding the PBSMC 
layer) or cell bodies in the mesenchyme. Vegfr2-positive cells (yellow), Pdgfrα-
positive cells (green) and Prox1-positive cells (light blue) lie within the SEM. Fgf10-
positive cells (dark red) reside in the SMM whereas Wt1-positive cells (dark blue) 
reside in the mesothelium. Note the presence of hematopoietic cells (red) in the 
lung mesenchyme. (B) FGF9, secreted by the mesothelium, induces proliferation 
and inhibits differentiation of Fgf10-positive cells via Wnt2a-mediated Wnt signaling. 
(C) VEGF-A, secreted by the epithelium and the mesenchyme, induces 
amplification and differentiation of Vegfr2-positive progenitor cells residing in the 
SEM. These cells give rise to the capillary plexus surrounding the epithelium. (D) 
FGF10, secreted by the SMM, acts via its epithelial receptor FGFR2b to induce 
branching morphogenesis as well as maintenance of epithelial progenitors. On the 
other hand, SHH and BMP-4, secreted by the epithelium, act as negative regulators 
of Fgf10 but induce mesenchymal proliferation and differentiation through PTC and 
BMPR respectively. Pdgfrα-positive cells in the SEM respond to epithelial PDGF-A 
and undergo proliferation. These cells eventually give rise to alveolar 
myofibroblasts during alveologenesis. Abbreviations: BMP-4: Bone morphogenetic 
protein 4; BMPR: Bone morphogenetic protein receptor; Epi: Epithelium; Mes: 
Mesenchyme; Meso: Mesothelium; PTC: Patched; SEM: Sub-epithelial 
mesenchyme; SHH: Sonic hedgehog; SMM: Sub-mesothelial mesenchyme; VEGF-
A: Vascular endothelial growth factor A; αSma: Alpha Smooth muscle actin. 
Adopted and modified from an H/E stained E13.5 lung section from (White et al., 
2006). 
1.2.2.1. Mesothelial-mesenchymal interactions: The SMM is under the 
effect of FGF9 signaling via the Wnt pathway 
Both being of mesodermal origin, the lung mesothelium and the adjacent 
mesenchyme undergo paracrine signaling that is critical for proper lung 
development. FGF9, secreted by the mesothelium, acts through the 
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mesenchymal splice variant (c) of Fibroblast growth factor receptor 1 and 2 
(FGFR1/2c) to induce proliferation of mesenchymal cells in the SMM, 
including Fgf10-positive cells (Colvin et al., 2001) (Fig. 5B). FGF9 maintains 
these cells in a progenitor-like state by preventing their differentiation to 
smooth muscle cells. Loss of function of β-Catenin in the lung mesenchyme 
using Dermo1Cre; β-Cateninflox system has shown that FGF9 effect on 
mesenchymal cells is mediated by Wnt signaling. Wnt2a seems to provide a 
permissive signal for FGF9 signaling, allowing the activation of β-Catenin 
signaling that leads to proliferation of mesenchymal cells in the SMM (White 
et al., 2006; De Langhe et al., 2008; Yin et al., 2008, 2011). Furthermore, Del 
Moral et al. have shown that FGF9 acts not only on the mesenchyme, but also 
on the epithelium to induce proliferation, but not differentiation, via Wnt 
signaling (Del Moral et al., 2006). 
1.2.2.2. Endothelial-epithelial interactions: VEGF-A/VEGFR2 signaling is 
critical for the formation of the capillary network 
The lung vasculature starts to develop as soon as the primary lung buds are 
formed (Gebb and Shannon, 2000). deMello et al. proposed a model in which 
central vessels (proximal) are formed by angiogenesis (branching of pre-
existing vessels) and peripheral vessels (distal) by vasculogenesis (in situ 
differentiation of endothelial progenitors). The two components fuse to form a 
continuous vascular lumen via a lytic process around E13/14 and the 
pulmonary circulation would be established (deMello et al., 1997). 
The earliest marker of endothelial cells in the developing lung is Flk-1 or 
Vegfr2 (Yamaguchi et al., 1993; Kappel et al., 1999). VEGF-A, an endothelial 
cell mitogen and angiogenic factor, is secreted by the developing epithelium 
as well as mesenchyme and it acts on Vegfr2-positive progenitor cells 
residing in the SEM (Bhatt et al., 2000; Del Moral et al., 2006) (Fig. 5C). 
These mesenchymal cells eventually give rise to the capillary plexus that 
surrounds the epithelium. Interestingly, Lugus et al. have reported that Vegfr2-
positive cells also give rise to primitive and definitive blood cells. The authors 
used Flk-1Cre/+; Rosa26RLacZ and Flk-1Cre/+; Rosa26ReYFP systems to 
demonstrate that hematopoietic cells residing in the lung mesenchyme derive 
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from resident Vegfr2-positive cells (Lugus et al., 2009). White et al. have 
shown that SHH (epithelial derived) and FGF9 (epithelial and mesothelial-
derived) upregulate the expression of Vegf-a in the lung mesenchyme (Fig. 
5C) (White et al., 2007). On the other hand, VEGF-A has also been shown to 
act indirectly on the lung epithelium. Del Moral et al. have shown that 
exogenous VEGF-A promotes branching morphogenesis in the epithelium 
and increases the proliferation index in both the epithelium and mesenchyme 
of E11 lung explants. VEGF-A upregulates Bmp-4 and Sftpc and induces 
proliferation of Vegfr2-positive cells (Del Moral et al., 2006). 
Endothelial-epithelial interactions have been shown to be critical for lung 
regeneration after pneumonectomy. Ding et al. have demonstrated that 
VEGFR2 and FGFR1 activation in pulmonary capillary endothelial cells is 
required for inducing MMP14 secretion. MMP14 unmasks EGFR ecto-
domains in the lung epithelium and thus increases the bioavailability of EGFR 
ligands. This mechanism induces the expansion of epithelial progenitors 
during compensatory lung growth (Ding et al., 2011). 
1.2.2.3. Epithelial-mesenchymal interactions: Paracrine signaling 
controls cell proliferation and differentiation in the epithelium and 
mesenchyme 
Epithelial-mesenchymal interactions are critical for proper lung development. 
Sonic hedgehog (SHH), Bone morphogenetic protein-4 (BMP-4), FGFs and 
Wnt ligands are diffusible molecules that mediate epithelial-mesenchymal 
interactions in the developing lung [Reviewed in (Shannon and Hyatt, 2004)]. 
SHH, secreted by the epithelium, acts through its mesenchymal receptor 
Patched (PTC) to induce mesenchymal cell proliferation and differentiation 
(Fig. 5D). Treatment of E11.5 lung explants with recombinant SHH has shown 
to upregulate mesenchymal markers including its own receptor (Ptc), Noggin, 
Sma and Myosin (Bellusci, Furuta, et al., 1997; Weaver et al., 2003). On the 
other hand, Bmp-4 has a dynamic expression pattern in the distal endoderm 
as well as the mesenchyme during early pseudoglandular stage (E11.5). Its 
expression is rather restricted to the epithelium beyond E13.5 (Fig. 5D). BMP-
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4 mediates epithelial-interactions and is critical for PBSMC formation (Weaver 
et al., 1999, 2003). 
One of the main features of SHH and BMP-4 signaling is inhibition of Fgf10 
expression. FGF10 is one of the key growth factors secreted by stromal cells 
in the distal mesenchyme (Bellusci, Grindley, et al., 1997). It acts in a 
paracrine fashion on the opposite epithelium expressing the epithelial isoform 
(b) of FGFR2-III (FGFR2-IIIb or simply FGFR2b) (Fig. 5D). FGF10/FGFR2b 
signaling is critical for proper lung development and disruption of this pathway 
by genetic manipulation leads to detrimental consequences that range from 
branching simplification to agenesis of the lung (Peters et al., 1994; Sekine et 
al., 1999; De Moerlooze et al., 2000; Perl and Gale, 2009). FGF10 promotes 
epithelial survival and branching and its dosage is crucial for the amplification 
of epithelial progenitors (Ramasamy et al., 2007). 
In the following section, the FGF superfamily will be introduced and the role of 
FGF10 during development and postnatal life will be reviewed. 
1.3. The FGF superfamily: From development to postnatal life 
Fibroblast growth factors (FGFs) constitute a family of polypeptides that are 
involved in diverse organogenetic programs during development as well as 
homeostatic balance during postnatal life. The FGF ‘story’ dates back to the 
mid-70s when Hugo A. Armelin observed that pituitary extracts have a 
proliferative effects on NIH3T3 fibroblasts growing in vitro (Armelin, 1973). 
The first FGFs (FGF1/2/3) were later purified from bovine brain and pituitary 
gland (Gospodarowicz, 1975; Gospodarowicz et al., 1978). To date, the FGF 
gene family has shown to consist of 22 members (FGF1-23). FGF15 has not 
been identified in humans whereas Fgf19 has not been identified in mouse 
and rat [Reviewed in (Itoh and Ornitz, 2011)]. 
According to their mode of action, FGFs can be classified into intracrine, 
endocrine and paracrine FGFs (Table 3). As the name suggests, intracrine 
FGFs (FGF11-14) are not secreted extracellularly and they do not require the 
FGF receptor (FGFR) to function. Rather, they are retained inside the cell 
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where they interact with other intracellular signaling pathways. Intracrine 
FGFs are believed to control the excitability of nerve cells (Goldfarb et al., 
2007; Shakkottai et al., 2009). Recently, it has been shown that Fgf13 
knockout mice suffer from impaired neuronal polarization and migration, in 
addition to weakened learning and memory. This phenotype mimics X-
chromosome-linked mental retardation (XLMR) in humans (Wu et al., 2012). 
Endocrine FGFs (FGF15/19, 21 and 23) are hormone-like FGFs and they are 
involved in multiple metabolic pathways, especially lipid metabolism. They 
have low affinities to FGFRs and heparin/heparan sulphate which enables 
them to function in a hormone-like fashion. Endocrine FGFs are believed to 
function in a common signal transduction pathway with the transmembrane 
protein Klotho, mediating lipid, bile acid, phosphate and vitamin D 
metabolisms (Shimada et al., 2004; Urakawa et al., 2006; Kurosu et al., 2007; 
Hotta et al., 2009). 
Table 3. Subfamilies of human FGF genes and the corresponding phenotypes 
of Fgf-/- mice. 
* FGF19 is the human ortholog of mouse Fgf15. ND: Not determined. Reviewed in 
(Ornitz and Itoh, 2001; Itoh and Ornitz, 2004, 2008, 2011; Itoh, 2007; Beenken and 
Mohammadi, 2009). 
 
 
Human 
gene 
Corresponding 
murine Fgf-/- 
phenotype 
Phenotype description 
P
a
ra
c
ri
n
e
 
FGF1 subfamily 
FGF1 Viable ND 
FGF2 Viable 
Cardiovascular, neuronal and skeletal 
defects 
FGF4 subfamily 
FGF4 Lethal E4-5 Blastocyst formation defect 
FGF5 Viable Hair development defect 
FGF6 Viable Impaired muscle regeneration 
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FGF7 subfamily 
FGF3 Viable Inner ear, tail and CNS defects 
FGF7 Viable Impaired hair and kidney development 
FGF10 Lethal P0 Impaired multi-organ development 
FGF22 Viable 
Impaired synapse differentiation and 
delayed weight gain 
FGF9 subfamily 
FGF9 Lethal P0 
Lung, heart, vascular, GI tract and 
testis developmental defects 
FGF16 Viable 
Impaired cardiac and facial 
development 
FGF20 Viable Impaired inner ear development 
FGF8 subfamily 
FGF8 Lethal E8 
Defects in gastrulation; brain, eye, ear 
and limb development 
FGF17 Viable Impaired hind brain development 
FGF18 Lethal P0 Impaired multi-organ development 
In
tr
a
c
ri
n
e
 
FGF11 subfamily 
FGF11 ND ND 
FGF12 Viable ND 
FGF13 Viable 
Impaired neuronal polarization and 
migration 
FGF14 Viable 
Ataxia; Paroxysmal hyperkinetic 
movement disorder 
E
n
d
o
c
ri
n
e
 
FGF19 subfamily 
FGF19* 
Lethal E13.5-
P7 
Impaired cardiac outflow tract 
morphogenesis and bile acid 
metabolism 
FGF21 Viable Impaired lipid metabolism 
FGF23 Lethal wk4-13 
Impaired phosphate and vitamin D 
metabolism 
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On the other hand, paracrine FGFs (FGF1, 4, 7, 9 and 8 subfamilies) bind 
with high affinities to heparin/heparan sulphate and strictly function via 
FGFRs. These FGFs are involved in multiple organogenetic programs such 
as heart, lung, brain, muscle, kidney, hair, ear, limb and craniofacial 
development. Depending on ligand-receptor specificity, these FGFs bind and 
activate epithelial (b) or mesenchymal (c) isoforms of FGFRs. Table 4 
summarizes the different FGFR isoforms and their corresponding FGF 
ligands. 
Table 4. Ligand-receptor specificity of human FGFRs. 
Demonstrated and reviewed in (Ornitz et al., 1996; Itoh and Ornitz, 2004; Zhang et 
al., 2006). 
 
Human Gene Protein Ligands 
FGFR1 
FGFR1b FGF1, 2, 3, 10 and 22 
FGFR1c FGF1, 2, 4, 5 and 6 
FGFR2 
FGFR2b FGF1, 3, 7, 10 and 22 
FGFR2c FGF1, 2, 4, 6 and 9 
FGFR3 
FGFR3b FGF1 and 9 
FGFR3c FGF1, 2, 4, 8 and 9 
FGFR4 FGFR4 FGF1, 2, 4, 6, 8 and 9 
To demonstrate the receptor-ligand specificity of FGF signaling, we carried 
out an experiment where embryonic lungs (E11.5) were isolated and allowed 
to grow in an air-liquid interphase in the presence of recombinant human 
FGF7, 9 or 10 (Fig. 6). Having FGFR2b as their main receptor, FGF7 and 
FGF10 act on the epithelium to induce proliferation/dilation (Fig. 6D-F) or 
migration/branching (Fig. 6J-L) respectively. On the other hand, FGF9 signals 
through epithelial as well as mesenchymal isoforms of FGFRs and induces 
epithelial dilation and mesenchymal thickening (Fig. 6G-I). 
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Figure 6. Recombinant FGFs confer unique effects on organotypic cultures in 
vitro. 
E11.5 lungs were cultured in an air-liquid interphase for 30 h. (A-C) Lung growing in 
the absence of exogenous recombinant growth factors. The epithelium undergoes 
branching morphogenesis and the mesenchyme becomes thinner over time. (D-F) 
In the presence of recombinant FGF7 (100 ng/mL), the epithelium is dilated at the 
expense of the mesenchyme. (G-I) Recombinant FGF9 (200 ng/mL) induces 
dilation of the epithelium as well as thickening of the mesenchyme. (J-L) Addition of 
recombinant FGF10 (250 ng/mL) enhances epithelial branching. Scale bar: 500 µm. 
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Since FGF10 is central in the reported project, we will discuss its role in 
embryogenesis and homeostasis in a more detailed manner in the following 
section. 
1.3.1. FGF10 is a key regulator of organogenesis, maintenance of 
epithelial progenitors and controls the formation of mesenchymal 
lineages during embryonic development 
Fgf10 was first reported in 1996 by Yamasaki et al. who used homology PCR 
to identify and isolate a novel Fgf cDNA from rat embryos. Being the 10th 
reported FGF at that time, it was named FGF10 (Yamasaki et al., 1996). One 
year later, the expression pattern of Fgf10 was described in the rat brain 
(Hattori et al., 1997) and its roles in chick limb bud outgrowth (Ohuchi et al., 
1997) and murine lung endoderm branching (Bellusci, Grindley, et al., 1997) 
were reported. FGF10 was proposed to have a chemotactic effect on the 
opposite endoderm expressing Fgfr2b (Bellusci, Grindley, et al., 1997; Park et 
al., 1998; Ohuchi et al., 2000). The role of FGF10 in lung and limb 
development was demonstrated by Fgf10- and Fgfr2b-null embryos that suffer 
from lung and limb agenesis (Sekine et al., 1999; De Moerlooze et al., 2000). 
FGF10 was also shown to be critical for the development of diverse organs 
and tissues including the prostate (Thomson and Cunha, 1999), white adipose 
tissue (Yamasaki et al., 1999; Sakaue et al., 2002), lacrimal glands 
(Makarenkova et al., 2000), thyroid (Ohuchi et al., 2000), pituitary gland 
(Ohuchi et al., 2000; Rosenfeld et al., 2000), kidney (Ohuchi et al., 2000), 
inner ear (Ohuchi et al., 2000; Pirvola et al., 2000), thymus (Ohuchi et al., 
2000; Revest et al., 2001), pancreas (Ohuchi et al., 2000; Bhushan et al., 
2001), mammary glands (Mailleux et al., 2002), incisors (Ohuchi et al., 2000; 
Harada et al., 2002), whiskers (Ohuchi et al., 2003), hair follicle (Ohuchi et al., 
2000; Petiot et al., 2003), cecum (Burns et al., 2004; Fairbanks, Kanard, et al., 
2004), anorectum (Fairbanks, De Langhe, et al., 2004), palate (Rice et al., 
2004), external genitalia (Satoh et al., 2004), duodenum (Kanard et al., 2005), 
colon (Fairbanks et al., 2005), urethra (Petiot et al., 2005), eyelids (Tao et al., 
2005), submandibular salivary glands (Ohuchi et al., 2000; Jaskoll et al., 
2005), stomach (Ohuchi et al., 2000; Nyeng et al., 2007) and liver (Berg et al., 
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2007). 
Early transcriptional targets of FGF10 during lung bud morphogenesis were 
studied by Lu et al. The authors used microarray analysis on mesenchyme-
free lung epithelial explants and in situ hybridization on intact embryonic lungs 
to show that FGF10 induces genes that are involved in cell rearrangement 
and migration, inflammatory processes, lipid metabolism and tumor invasion. 
No proliferative effect on the lung epithelium was observed (Lu et al., 2005). 
The currently accepted mode of action for FGF10 on the lung epithelium 
during development is divided into two parts: Chemotaxis and maintenance of 
epithelial progenitors. The chemotactic function of FGF10, related to its 
dynamic expression pattern, is demonstrated by the perturbed branching 
pattern in Fgf10-overexpressing lungs (Clark et al., 2001). More recently, it 
has been suggested that FGF10 controls the mitotic spindle orientation in the 
developing epithelium via RAS-regulated ERK1/2 signaling pathway, thus 
determining lung tube shape (Tang et al., 2011). On the other hand, FGF10 is 
critical for the maintenance of epithelial cells in a progenitor-like state. While 
Fgf10-null embryos suffer from arrested growth in the pancreas and stomach 
(Bhushan et al., 2001; Nyeng et al., 2007), Fgf10 overexpression leads to the 
expansion of epithelial progenitors and attenuation of epithelial differentiation 
in these organs (Norgaard et al., 2003). A similar effect is also seen in the 
lung where gain of function of Fgf10 during development leads to progenitor 
state arrest and distalization of the lung (Nyeng et al., 2008). Finally, Fgf10 
inactivation reveals a decrease in epithelial progenitors in the colon (Sala et 
al., 2006). 
During murine lung development, FGF10 functions in a dose-dependent 
manner as hypomorphic Fgf10 lungs reveal branching simplification as well as 
vascular abnormalities (demonstrated by the simplification of the vascular tree 
and the presence of large hemorrhagic areas). Decreased Fgf10 expression 
in Fgf10-LacZ/- lungs is coupled with a decrease in the number of Ttf-1 and 
Sp-B-expressing cells, indicating that Fgf10 dosage is critical for the 
amplification of epithelial progenitors. Mesenchymal lineages such as the 
endothelium and smooth muscle are also affected in Fgf10-LacZ/- lungs. 
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These lungs have decreased numbers of Pecam and αSma-positive cells 
(Ramasamy et al., 2007). 
The role of FGF10 in the formation of smooth muscle during early lung 
development was demonstrated by Mailleux et al. The authors used the 
Fgf10-LacZ line to show that LacZ-expressing cells, originally located in the 
distal mesenchyme, migrate proximally and relocate around the epithelium 
giving rise to PBSMCs (Mailleux et al., 2005). As a follow up on this finding, 
De Langhe et al. have shown that β-Catenin signaling in the mesenchyme, 
mediated by the PITX family of transcription factors, is critical for the 
amplification but not the differentiation of Fgf10-expressing progenitor cells 
(De Langhe et al., 2008). 
Taken together, the aforementioned data demonstrate that during lung 
development, Fgf10 orchestrates epithelial branching and maintains epithelial 
progenitors. In the mesenchyme, Fgf10-expressing cells are progenitors for 
PBSMCs and Fgf10 dosage is critical for the formation of multiple 
mesenchymal lineages. 
1.3.2. Role of FGF0 in homeostasis and wound healing during postnatal 
life 
After birth, Fgf10 transcripts are detected at considerable levels in the lung 
during the alveolar stage (P5-P30) as well as during adulthood (Fig. 7).This 
implies that the role of this growth factor is not limited to embryonic life but 
rather extends to postnatal life. However, the role of FGF10 in lung 
homeostasis during postnatal life is poorly understood. 
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Figure 7. Fgf10 expression levels increase throughout development and are 
maintained postnatally. 
Relative expression levels of Fgf10 during embryonic development and postnatally 
as determined by quantitative real-time PCR (qPCR) on Fgf10iCre/+ background. 
Fgf10 expression levels increase throughout development and then decrease after 
birth. Fgf10 expression is sustained during adulthood. Reference gene: β-actin. 
Ramasamy et al. have shown that lungs that are hypomorphic for Fgf10 have 
impaired septation/alveolarization postnatally (Ramasamy et al., 2007). 
Moreover, inactivation of FGFR2b signaling prenatally – but not postnatally – 
leads to emphysema (Hokuto et al., 2003). Yet, it has been suggested that 
FGFR2b ligands are not needed for normal lung homeostasis; rather they are 
required for repair and restoring homeostasis after hyperoxia (Hokuto et al., 
2004) and naphthalene injury (Volckaert et al., 2011). In the latter study, it 
was demonstrated that Fgf10 expression is induced in PBSMCs and that 
FGF10/FGFR2b signaling between PBSMCs and surviving variant Clara cells 
is critical for epithelial regeneration. 
On the other hand, FGF10/FGFR2b signaling is critical for normal 
homeostasis of other organs and tissues such as the incisors, mammary 
glands and osteoblasts. It has been shown that FGF10/FGFR2b signaling 
controls the regenerative capacity of the adult mouse incisors. Attenuation of 
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FGFR2b signaling using a dominant negative approach leads to decreased 
amplification of the transient-amplifying cells that are progenitors of the 
enamel-producing cells in the mouse incisors (Parsa et al., 2010). Similarly, 
attenuating FGFR2b signaling postnatally yields a rudimentary mammary 
epithelial tree and the absence of terminal end buds (Parsa et al., 2008). 
Lastly, FGFR2 attenuation throughout development and postnatally has 
shown to regulate osteoblast function and bone growth (Yu et al., 2003). 
In the lung, Fgf10 overexpression postnatally has shown to produce reversible 
adenomas in addition to enriching the lung with Sftpc-positive cells (Clark et 
al., 2001). This is consistent with the role of FGF10 during lung development 
in inducing epithelial cell migration/invasion (Lu et al., 2005) and maintaining 
distal epithelial progenitors (Nyeng et al., 2008). However, FGF10 has shown 
to have anti-fibrotic properties as Fgf10 overexpression is preventive and 
therapeutic against bleomycin-induced pulmonary fibrosis in mice (Gupte et 
al., 2009). We speculate that FGF10 is a vital survival factor for AEC II and it 
antagonizes the detrimental effect of TGF-β signaling during fibrosis. 
Studying the function of FGF10 postnatally is clinically relevant because many 
human disorders related to FGF10 mutations have been reported. Mutations 
in the human FGF10 gene are associated with autosomal dominant Aplasia of 
lacrimal and salivary glands (ALSG) (Entesarian et al., 2005, 2007). These 
individuals suffer from irritable eyes and dryness of the mouth. Another 
autosomal dominant anomaly caused by FGF10 mutations is the Lacrimo-
auriculo-dento-digital (LADD) syndrome. This syndrome is characterized by 
aplasia, atresia or hypoplasia of the lacrimal and salivary glands, cup-shaped 
ears, hearing loss and dental and digital abnormalities (Milunsky et al., 2006). 
Moreover, recent evidence suggests that FGF10 mutations are associated 
with Autism spectrum disorder (ASD) (Casey et al., 2012). ASD patients suffer 
from social and communicative difficulties. Furthermore, FGF10 
haploinsufficiency has been shown to be associated with chronic obstructive 
pulmonary disease (COPD). Lung function parameters from these patients 
indicate COPD and the modest response to treatment confirms irreversibility 
of the disease (Klar et al., 2011). 
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2. Objectives 
The lineage tree of the lung epithelium has been thoroughly studied. Lineage 
tracing experiments during embryonic development, postnatal homeostasis 
and repair after injury have shown that basal cells can regenerate both ciliated 
and secretory cells and are thus on top of the hierarchy of epithelial lineages 
(Hong et al., 2004; Rock et al., 2009). These cells, in addition to variant Clara 
cells in NEBs and BADJs, have the ability to regenerate the adult lung 
epithelium (Stripp et al., 1995; Giangreco et al., 2002). On the other hand, the 
mesenchyme holds as the ‘black box’ of the lung. This compartment of the 
lung is populated by multiple cell types belonging to myogenic, adipogenic, 
chondrogenic and other lineages. Yet, no clear hierarchy for these lineages 
has been established. 
Over the past few years, Fgf10-expressing cells have emerged as progenitors 
for PBSMCs during early lung development (Mailleux et al., 2005). Induced 
Fgf10 expression in PBSMCs during postnatal life has shown to be critical for 
the initiation of epithelial repair in the context of naphthalene-induced 
epithelial injury (Volckaert et al., 2011). Moreover, FGF10 has shown to 
counteract the fibrotic effect of bleomycin administration (Gupte et al., 2009). 
Finally, FGF10 is required for the growth of epithelial stem cells in vitro 
(McQualter et al., 2010). 
The work presented in this dissertation is intended to explore the status of 
Fgf10-positive cells in the lineage hierarchy of the lung mesenchyme. In the 
first part of the Results section, we show the validation aspect of a novel 
Fgf10 inducible Cre (Fgf10iCre) knock-in mouse line that allows specific 
labeling of Fgf10-expressing cells, which can be lineage-traced temporally 
and spatially (El Agha et al., 2012). In the second part, we show the main 
findings from the lineage tracing work that was carried out using this line [(El 
Agha et al., Fgf10-positive cells represent a progenitor cell population during 
lung development and postnatally; in revision) and (Al Alam, El Agha et al., 
Fgf10 identifies lipofibroblast progenitors and controls their lineage 
commitment during lung development; in progress)]. We used time-lapse 
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fluorescence imaging on intact embryonic lungs to study the behavior of these 
cells during ex vivo lung growth. We also performed histological analysis on 
lung tissues as well as FACS analysis on disaggregated lungs to identify the 
progeny of Fgf10-expressing cells and explore surface markers that help to 
position these cells in the lineage tree of the lung mesenchyme. Lineage 
tracing was carried out during embryonic development, neonatally (during the 
alveolar stage of lung development) and postnatally (in the context of lung 
fibrosis). We also investigated the role of FGF10 in the formation of the 
adipogenic lineage in the lung (lipofibroblasts) using primary cultures of 
embryonic lung mesenchyme as well as embryonic human lung fibroblast cell 
line (WI-38) as models to study FGF10-mediated adipogenesis in vitro. 
The aims of the reported work are summarized as the following: 
1. Validation of a novel Fgf10iCre knock-in mouse line that allows inducible 
genetic labeling and manipulation of Fgf10-expressing cells in vivo 
 
2. Studying the behavior and identifying the progeny of Fgf10-positive cells 
at multiple embryonic stages as well as postnatally 
 
3. Identifying surface markers that allow better characterization of these 
cells 
 
4. Studying the role of these cells in the context of lung fibrosis 
 
5. Investigating the role of FGF10 in the formation of the adipogenic 
lineage in the lung (lipofibroblasts) in vivo and in vitro. 
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3. Materials and Methods 
3.1. Targeting strategy of the endogenous Fgf10 locus to 
generate C57BL/6-Fgf10Cre-ERT2-eYFP/J knock-in mice 
5’ and 3’ homology regions (10.3 kb) for Fgf10 were amplified by PCR using 
DNA from an Fgf10-specific BAC clone derived from a BAC library of 
129Sv/AB2.2 mouse strain (Wellcome Trust Sanger Institute, Cambridge, 
UK). The isolated sequences were used to design the targeting construct. The 
linearized targeting construct was transfected into TVB2 mouse ES cells 
(following the electroporation procedure: 5 x 106 ES cells in presence of 40 μg 
of linearized plasmid, 260 Volt, 500 μF). Positive selection was started 48 h 
after electroporation by addition of 200 μg/mL of G418. G418-resistant 
colonies were selected based on cell growth and morphology. One 
electroporation session was performed and a total of 209 clones were isolated 
and amplified in 96-well plates. Duplicates of 96-well-plates were made; one 
copy was frozen down and the other copy was amplified on gelatine to be 
used for genomic DNA preparation. Clones were screened by PCR for 
homologous recombination and verified by Southern blotting. Altogether, 
PCR, sequencing and Southern blot screening allowed the characterization of 
ten recombined clones, seven of which were suitable for blastocyst injection. 
Recipient blastocysts were isolated from pregnant C57BL/6J females (Health 
status VAF – Virus antibody free). Based on screening results and 
morphological criteria, ES cell clones were injected into C57BL/6J blastocysts. 
Injected blastocysts were then re-implanted into OF1 pseudo-pregnant 
females and allowed to develop to term. Four of the highly chimeric males 
generated were selected to breed with C57BL/6J Flp-deleter mice (health 
status SOPF – Specific and opportunist pathogen free) to allow germline 
excision of the neomycin selection cassette. 
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3.2. Genotyping of C57BL/6-Fgf10Cre-ERT2-eYFP/J knock-in 
mice 
Two primer pairs were used to genotype Fgf10iCre knock-in mice. Primers P1 
(5'-AGCAGGTCTTACCCTTCCAGTATGTTCC-3') and P2 (5'-
CTCCTTGGAGGTGATTGTAGCTCCG-3') were used to detect the wild-type 
allele (297 bp band) whereas primers P3 (5'-
CAAACCCCAAAAGAACAGCTTTGTGTAC-3') and P4 (5'-
GACATTTGAGTTGCTTGCTTGGCACT-3') were used to detect the knock-in 
allele (271 bp band). The PCR program consists of a denaturation step at 
94°C for 2 min, followed by 35 cycles of denaturation (94°C for 30 s), 
annealing (65°C for 30 s) and extension steps (68°C for 300 s). The program 
ends with a completion step at 68°C for 480 s. Each PCR tube contains 2.6 U 
of Expand Long Template Polymerase in 5 µL of Reaction buffer 3 (Roche 
Applied Science, Mannheim, Germany), 15 pmol of each primer, 0.5 mM 
dNTPs and 10 ng of genomic DNA in a final volume of 50 µL. 
3.3. Mice and tamoxifen administration 
Tomatoflox/flox reporter mice (B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J) 
were purchased from Jackson lab (stock number 007905) and Fgf10flox/flox 
mice were a kind gift from Professor Suzanne L. Mansour (University of Utah, 
USA). Embryonic day 0.5 (E0.5) was assigned to the day when a vaginal plug 
was detected. Mice were housed in a Specific pathogen free (SPF) 
environment. Harvesting organs and tissues from wild type and transgenic 
mice was approved by Justus Liebig University Giessen (Approval numbers 
405_M and 437_M). Animal experiments were approved by the 
Regierungspräsidium Giessen. Tamoxifen injections were approved in (GI 
20/10 Nr. 38/2011 and 117/2012) and bleomycin treatment was approved in 
the amendment to (GI 20/10 Nr. 73-2012). 
Tamoxifen stock solution was prepared by dissolving tamoxifen powder 
(T5648, Sigma, Schnelldorf, Germany) in corn oil at a concentration of 20 
mg/mL at room temperature (RT). Pregnant females carrying Fgf10iCre/+; 
Tomatoflox/+ embryos received a single intraperitoneal (IP) injection of 0.1 mg 
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of tamoxifen per gram of body weight. For continuous tamoxifen exposure, 
pregnant females were fed tamoxifen-containing food (0.4 g of tamoxifen per 
kg of food) (Altromin, Lage, Germany). Dissected embryos and lungs were 
examined using Leica M205 FA fluorescence stereoscope (Leica, Wetzlar, 
Germany) and images were acquired using Leica DFC360 FX camera. 
Cecum lengths were measured using Leica’s LAS AF software and digit 
peripheries were measured using Image J software (NIH, Bethesda, MD, 
USA). 
3.4. Organ culture and time-lapse microscopy 
Embryonic lungs were harvested in Dulbecco's Modified Eagle's Medium 
(DMEM) and cultured on Whatman Nuclepore membrane filters (GE 
Healthcare, Solingen, Germany) placed on 500 µL of DMEM with 10% Fetal 
Bovine Serum (FBS) and 1% Penicillin/Streptomycin. Culture dishes with 
embryonic lungs were then transferred into the culture chamber (37°C; 5% 
CO2) of Leica DMI6000 B live imaging microscope and time-lapse imaging 
was performed. RFP signal intensity was measured using Image J software. 
3.5. X-Gal staining 
X-Gal staining was performed as previously described (Al Alam et al., 2011). 
Briefly, Fgf10-LacZ lungs were dissected in Hank’s Balanced Salt Solution 
(HBSS) (Invitrogen, Darmstadt, Germany) from E18.5 embryos, shortly fixed 
in 4% Paraformaldehyde (PFA), washed in PBS and incubated with LacZ 
buffer solution for 10 min. Then, they were incubated with LacZ buffer solution 
containing 40 mg/mL X-Gal (Sigma) at 37°C overnight. 
3.6. Quantitative real-time PCR and RT-PCR 
Freshly harvested embryos, lungs or cells were lysed and RNA was purified 
using RNeasy or miRNeasy kit (Qiagen, Hilden, Germany). E11.5 and E13.5 
embryos as well as harvested cells were homogenized using QiaShredder 
columns (Qiagen) whereas lungs from older tissues were homogenized using 
Bullet Blender Blue (Next Advance, Averill park, NY, USA). 1 µg of RNA was 
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used for cDNA synthesis using Quantitect Reverse Transcription kit (Qiagen). 
Primers and probes were designed using Universal ProbeLibrary Assay 
Design center (Roche Applied Science, available online at https://www.roche-
applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000). More details about 
the used primers and probes can be found in Supplementary Table S2. 
Quantitative real-time PCR (qPCR) was performed using LightCycler 480 real-
time PCR machine (Roche Applied Science). Samples were run in triplicates 
using mouse β-actin (for TaqMan® assays), mouse Hprt or human PBGD (for 
SYBR® Green assays) as reference genes and the ΔΔCT method was used 
for relative quantification. 
3.7. Bleomycin administration and lung function measurement 
Female mice were anesthetized with a mixture of Ketamine (0.6 µL/g) (Bela-
pharm, Vechta, Germany) and Domitor® (0.3 µL/g) (Janssen animal health, 
Neuss, Germany) mixed in saline solution. The corneas were protected by 
Bepanthen® ointment (Bayer, Leverkusen, Germany). Once the animals were 
anesthetized, they were intubated oro-tracheally under a dissecting 
microscope. Bleomycin injections (Hexal, Holzkirchen, Germany) were given 
intratracheally with a 20G plastic catheter and microsprayer (3.5 U of 
bleomycin per kilogram of body weight in 50 µL of saline). Control groups 
were injected with saline instead of bleomycin. 
Fourteen days after treatment, mice were deeply anesthetized with Ketamine 
(1.2 µL/g), Domitor® (0.6 µL/g) and 1:4 parts of Heparin (Ratiopharm, Ulm, 
Germany) mixed in saline solution. 2% Xylocaine analgesic (Astra Zeneca, 
Wedel, Germany) was applied to the surgical area. The animals were then 
tracheotomized and intubated with a 20G cathether connected to a 
FlexiVentTM plesythmograph (Scireq, Montreal, QC, Canada). Lungs were 
mechanically ventilated at a rate of 150 breaths/min with a positive end-
expiratory pressure (PEEP) of 1-3 cmH2O. PEEP was calculated 
automatically by FlexiVent 7 software and according to the weight of each 
animal. After stabile ventilation was achieved, a 3 s tidal volume of 10 µL/g of 
body weight was initiated every 15-20 s and the single compartment model of 
lung mechanics (snapshot perturbations) was used to measure lung function 
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parameters (compliance, elastance and resistance). After plesythmography, 
animals were euthanized by cervical dislocation and lungs were isolated for 
further processing. 
3.8. Tissue processing and immunostaining 
Freshly isolated lungs were washed in PBS and then fixed in 4% PFA/PBS 
according to standard procedures. Then, tissues were embedded in paraffin 
and sectioned at 5 µm thickness. Slides were deparaffinized and then blocked 
with 3% BSA and 0.4% Triton-X (in TBS) at RT for 1 h. Then, they were 
incubated with primary antibodies at RT for 1 h or at 4°C overnight. Primary 
and secondary antibodies are summarized in Table 5. After incubation with 
antibodies, slides were washed three times in TBST (TBS buffer + 0.1% 
Tween20) for 5 min. Slides were mounted with Prolong® Gold Anti-fade 
Reagent with DAPI (Invitrogen). The endogenous Tomato signal was detected 
using the RFP channel. Fluorescent images were acquired using Leica 
DM5500 B fluorescence microscope and Leica DFC360 FX camera. 
Table 5. Antibodies used for immunofluorescence. 
 
Antibodies Host / Isotype Supplier Dilution 
Primary Antibodies 
Monoclonal FITC αSMA antibody  Mouse / IgG2a Sigma 1:100 
Polyclonal purified ADFP antibody Rabbit / IgG Abcam 1:50 
Monoclonal Neuron-specific beta-
III Tubulin antibody  
Mouse / IgG2a 
(clone Tuj-1) 
R&D 1:50 
FITC anti-mouse CD45 Antibody Rat / IgG2b, κ Biolegend 1:100 
FITC anti-mouse CD31 Antibody Rat / IgG2a, κ Biolegend 1:100 
Secondary Antibodies 
Alexa Fluor®-488 anti-rabbit  Goat Invitrogen 1:1000 
Alexa Fluor®-488 anti-mouse  Donkey Invitrogen 1:1000 
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3.9. FACS analysis 
Lungs were dissected, washed with HBSS and kept on ice. Then, they were 
cut into fine pieces using a sharp blade before being digested with 0.5% 
Collagenase Type IV/HBSS (Life Technologies, Invitrogen) at 37°C for 45 
min. Single cell suspensions were obtained by passing lung homogenates 
through 18, 21 and 24G syringes before being passed through 70 and 40 µm 
cell strainers (BD Biosciences, Heidelberg, Germany). Cell count was 
determined using a Neubauer hemocytometer (Labor Optik, Friedrichshof, 
Germany) and Trypan Blue was used to distinguish between live and dead 
cells. Cells were then resuspended in cold staining solution (0.1% Sodium 
Azide/5% FCS/0.05% Triton-X in 1x PBS) and antibodies were added 
according to Table 6. Cells were incubated with antibodies (Biolegend, Fell, 
Germany) for at least 30 min on ice in the dark and then washed with 0.1% 
Sodium Azide in PBS. The endogenous Tomato signal was detected using 
the PE channel. FACS measurements were carried out using FACSAria III 
cell sorter (BD Biosciences). Tomato-positive cells from unstained lung 
suspensions were sorted and grown in the presence (250 ng/mL) or absence 
of recombinant human FGF10 (rhFGF10) (R&D Systems, Wiesbaden, 
Germany) and were then stained for ADRP (Abcam, Cambridge, UK) and P-
ERK (New England Biolabs, Frankfurt, Germany) or harvested for RT-PCR. 
Table 6. Antibodies used for FACS analysis. 
 
Antibodies Host / Isotype Supplier Dilution 
FITC anti-mouse CD45 Rat / IgG2b, κ Biolegend 1:100 
FITC anti-mouse CD31 Rat / IgG2a, κ Biolegend 1:100 
APC-Cy7 anti-mouse EpCAM Rat / IgG2a, κ Biolegend 1:50 
Pacific Blue anti-mouse Sca-1 Rat / IgG2a, κ Biolegend 1:100 
APC anti-mouse CD140a Rat / IgG2a, κ Biolegend 1:100 
PE-Cy7 anti-mouse CD117 Rat / IgG2b, κ Biolegend 1:50 
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3.10. Primary culture of lung mesenchyme 
Single cell suspensions were obtained as described in Part 3.9. Instead of 
immunostaining, cells were plated for 45 min in DMEM with 10% FBS and 1% 
Penicillin/Streptomycin for differential adhesion (Lebeche et al., 1999). Culture 
flasks were then washed with sterile PBS, the medium was refreshed and 
cells were allowed to grow overnight in a humidified cell culture incubator at 
37°C and 5% CO2. Cell were then treated with rhFGF10 and stained for P-
ERK, or harvested for Western blotting or RNA extraction. 
3.11. WI-38 cell line 
Human embryonic lung fibroblast cell line WI-38 (ATCC® number CCL-75) 
was cultured according to manufacturer's instructions. Cells were grown in the 
presence or absence of different concentrations of rhFGF10 (0; 1; 10; 100; 
250 ng/mL) and were harvested for Western blotting or RNA extraction. 
3.12. Western blotting 
Cultured lung primary mesenchymal cells and cell lines were disrupted 
immediately in RIPA buffer (Sigma) containing protease inhibitors. Equal 
amounts of total lung protein from each assayed sample were used for 
chemiluminescent Western analysis on Immuno-Blot PVDF membrane (Bio-
Rad, Hercules, CA, USA). Immunoblotting was performed using antibodies 
against PTHrP receptor (1:200), PPAR (1:200), Leptin (1:200), C/EBP 
(1:200) and GAPDH (1:10000) (Santa Cruz Biotechnology, Dallas, TX, USA). 
3.13. Statistical analyses and figure assembly 
Quantitative data were assembled using GraphPad Prism software 
(GraphPad Software, La Jolla, CA, USA) and presented as average values ± 
S.E.M. Statistical analyses were performed using Student’s t-test (for 
comparing two groups) or One-way ANOVA (for comparing three or more 
groups). Data were considered significant if P < 0.05. Figures were 
assembled using Adobe Photoshop CS5. 
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4. Results 
This section will be divided into three parts: Part 4.1. Characterization of a 
novel Fgf10 knock-in mouse line to target mesenchymal progenitors during 
embryonic development, Part 4.2. Fgf10-positive cells constitute a progenitor 
cell population during lung development and represent a subpopulation of 
resident mesenchymal stem cells during postnatal life, and Part 4.3. Role of 
FGF10 in lipofibroblast formation in vivo and in vitro. 
4.1. Characterization of a novel Fgf10 knock-in mouse line to 
target mesenchymal progenitors during embryonic 
development 
4.1.1. Generation of Fgf10iCre (C57BL/6-Fgf10Cre-ERT2-eYFP/J) driver 
line 
129Sv ES cells were electroporated with a targeting vector containing the 5’ 
end of exon 1 of Fgf10 open reading frame (Fig. 8A, B). Immediately 
downstream of the start codon is the coding sequence of a tamoxifen-
inducible form of Cre recombinase (Cre-ERT2), followed by IRES sequence, 
eYFP and Neomycin-resistance gene (Neo) respectively. Resistant ES cell 
clones were selected, screened by PCR and then verified by Southern 
blotting. Selected ES clones were injected into C57BL/6J blastocysts to 
generate chimeric pups (Fig. 8C). Chimeras were then crossed with C57BL/6J 
mice ubiquitously expressing Flp recombinase to generate heterozygous 
Fgf10iCre knock-in mice where the Neo cassette was totally excised (Fig. 8D). 
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Figure 8. Generation of recombinant Fgf10iCre locus. 
(A, B) Cre-ERT2-IRES-eYFP-Neo construct was introduced in frame with ATG of 
exon 1 by homologous recombination. Genes coding for Neomycin resistance and 
Diphtheria Toxin A were used for positive and negative selection respectively. (C) 
Chimeras carrying the Neo cassette were crossed with C57BL/6J mice ubiquitously 
expressing Flp recombinase to generate heterozygous knock-in mice lacking the 
Neo cassette (D). Primers used for genotyping are shown as black arrows. Note 
that primers P1 and P2 detect the wild-type locus (297 bp band) whereas primers 
P3 and P4 detect the recombined locus (271 bp band). Abbreviations: C: Control; 
DTA: Diphtheria Toxin A; eYFP: Enhanced yellow fluorescent protein; IRES: 
Internal ribosome entry site; Neo: Neomycin-resistance gene; pGK: 
Phosphoglycerate kinase promoter. 
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4.1.2. Insertion of the Cre-ERT2 cassette in exon 1 results in Fgf10 loss 
of function 
To determine whether the insertion of Cre-ERT2 in the endogenous Fgf10 
locus led to loss of function of Fgf10, Fgf10iCre heterozygous animals were 
crossed and embryos were harvested at E12.5. Fgf10iCre homozygous 
embryos suffered from lung and limb agenesis in addition to cecal and colonic 
atresia, consistent with complete loss of function of Fgf10 (Fig. 9A-C; n = 4; 
penetrance = 100%). Fgf10iCre/+ embryos were used as controls. qPCR 
revealed minimal expression levels for Fgf10 in Fgf10iCre/iCre embryos (Fig. 9D; 
n = 4) compared to Fgf10iCre/+ (Fig. 9D; n = 5; P < 0.001) and Fgf10+/+ 
embryos (Fig. 9D; n = 5; P < 0.001). 
 
 
Figure 9. Fgf10iCre is a null allele for Fgf10. 
E12.5 Fgf10iCre/iCre embryos show agenesis of the limbs (A, A’) and lung (B, B’) as 
well as cecal and colonic atresia (C, C’). Arrowheads indicate sites of limb agenesis 
and dashed lines mark the epithelium in the cecum. Fgf10iCre/+ embryos were used 
as controls. (D) Fgf10 relative mRNA levels as quantified by qPCR. Fgf10iCre/iCre 
embryos (n = 4) express minimal Fgf10 levels compared to Fgf10iCre/+ (n = 5) and 
Fgf10+/+ embryos (n = 5). Data are shown as average values ± S.E.M. * P < 0.05; 
*** P < 0.001. Reference gene: β-actin. Abbreviations: Ce: cecum; Co: colon. 
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4.1.3. Labeling of Fgf10-positive cells 
In order to test the recombinase activity of Cre-ERT2, Fgf10iCre heterozygous 
mice were crossed with Tomatoflox/flox reporter mice. Pregnant females 
received a single IP injection of tamoxifen or corn oil at E15.5 and embryos 
were harvested at E18.5. No recombination was observed in Fgf10+/+; 
Tomatoflox/+ embryos (Fig. 10A-D; n = 4). Recombination was observed in the 
ears (Fig. 10A’, A’’), skin (Fig. 10B’, B’’), limbs (Fig. 10C’, C’’), ceca (Fig. 10D’, 
D’’) and lungs (Fig. 11A’-C’) of Fgf10iCre/+; Tomatoflox/+ embryos (n = 3; 
penetrance = 100%). Labeled cells in the skin were arranged in discrete spots 
(Fig. 10B’, B’’). In the limbs, labeled cells were abundant at the tips of the 
digits as well as more proximal regions (Fig. 10C’, C’’). In the cecum, 
however, elongated cells were labeled (Fig. 10D’, D’’). 
When examining the lungs from Fgf10iCre/+; Tomatoflox/+ embryos, Tomato-
positive cells were detected throughout the mesenchyme (Fig. 11A’; n = 3). 
Interestingly, the signal was intense in interlobular septa (Fig. 11B’). In the 
trachea, Tomato-positive cells were arranged in ring-like structures (Fig. 
11C’). X-Gal staining of Fgf10-LacZ lungs at E18.5 revealed similar sites of 
Fgf10 expression (Fig. 11A’’-C’’; n = 8). The expression of the eYFP reporter 
from the IRES sequence could not be detected in any of the embryos or 
lungs. Tomato-positive cells were not detected in Fgf10iCre/+; Tomatoflox/+ lungs 
from corn oil-injected females (Data not shown; n = 6). 
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Figure 10. Tomato expression in E18.5 Fgf10iCre/+; Tomatoflox/+ embryos. 
Recombination was induced at E15.5 by a single IP injection of tamoxifen. Note the 
absence of Tomato expression in Fgf10+/+; Tomatoflox/+ embryos (A-D). Tomato-
positive cells are detected in the ear, skin, limbs and cecum (A’-D’). (A”-D”) Higher 
magnifications of dotted boxes in (A’-D’). n = 3. Tam: Tamoxifen. 
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Figure 11. Tomato expression in E18.5 Fgf10iCre/+; Tomatoflox/+ lungs. 
Recombination was induced at E15.5 by a single IP injection of tamoxifen. Note the 
absence of Tomato expression in Fgf10+/+; Tomatoflox/+ lungs (A; n = 3). The regions 
in the dotted boxes are magnified in (B) and (C). Tomato-positive cells are 
observed in the lung mesenchyme and interlobular septa of Fgf10iCre/+; Tomatoflox/+ 
lungs (white arrows) (A’, B’; n = 3). Inset in B’ shows high magnification of 
interlobular septa. Labeled cells in the trachea arrange in ring-like structures (black 
arrows) (C’; n = 3). (A’’-C’’; n = 8) X-Gal staining of Fgf10-LacZ lungs at E18.5. 
Inset in B” shows high magnification of interlobular septa. 
4.1.4. Inducible conditional gene inactivation 
To test the potential use of this line for gene inactivation studies, Fgf10iCre/+; 
Tomatoflox/flox mice were crossed with mice carrying a ‘floxed’ version of Fgf10 
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(Fgf10flox/flox). Cre activity was induced by tamoxifen food from E8.5 to E14.5. 
By using the Tomatoflox reporter as readout of Cre activity, recombination was 
observed in the limbs, lungs and ceca (Fig. 12C, D, G, H, L; n = 3; penetrance 
= 100%). Fgf10iCre/flox; Tomatoflox/+ embryos suffered from diverse 
developmental abnormalities (n = 3; penetrance = 100%). A formation defect 
characterized by webbed digits was observed at the level of the forelimbs as 
compared to their Fgf10+/flox; Tomatoflox/+ control littermates. The phenotype 
was quantified by measuring the periphery of the digits (Fig. 12H vs. E, M; P < 
0.0001). Hindlimbs did not show any obvious abnormalities. The lung showed 
an abnormal shape and suffered from branching simplification as illustrated by 
the reduced number of terminal buds in the accessory lobe (Fig. 12C vs. B, G 
vs. F, J; P < 0.05). The cecum, on the other hand, was shorter in Fgf10iCre/flox; 
Tomatoflox/+ embryos as compared to littermate controls (Fig. 12L vs. I, K; P < 
0.05). 
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Figure 12. Inducible conditional Fgf10 inactivation using Fgf10iCre driver line. 
Cre was activated by tamoxifen food from E8.5 to E14.5 in Fgf10iCre/flox; Tomatoflox/+ 
embryos. Labeled cells are present in the limbs, lung and cecum (D, G, H, L). Note 
the webbing of the digits in the forelimbs (arrows indicate webbing sites and dashed 
lines indicate peripheries) (H vs. E, M) and the hypomorph-like phenotype in the 
cecum (L vs. I, K). Fgf10iCre/flox; Tomatoflox/+ lungs show a deformed shape (C vs. B) 
as well as branching simplification (G vs. F, J). Dashed lines indicate the epithelium 
in the lung (F, G) and cecum (I, L). n = 3. Data are shown as average values ± 
S.E.M. * P < 0.05; **** P < 0.0001. Embryonic tissues were kindly provided by Dr. 
Denise Al Alam (CHLA, CA, USA, Protocol number 31-11). 
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4.1.5. Mismatch between Cre and Fgf10 expression levels 
In order to investigate the expression levels of Cre from the Fgf10iCre locus, 
timed-pregnant females carrying Fgf10iCre/+ embryos were sacrificed at 
different developmental stages and Fgf10 and Cre expression levels were 
assessed by qPCR by comparing mRNA abundance from different stages to 
E11.5. Fgf10 expression levels progressively increased in Fgf10iCre/+ embryos 
from E11.5 (n = 5) to E13.5 (n = 3; P < 0.01) and E18.5 (n = 7; P < 0.001) and 
were maintained postnatally at P2 (n = 2; P < 0.05), P12 (n = 4; P < 0.0001) 
and P161 (n = 3; P < 0.001); however, Cre expression levels, from the same 
embryos, showed a slower increase from E11.5 (n = 5) to E13.5 (n = 3; P < 
0.05) and E18.5 (n = 7; P < 0.01) and then dropped postnatally at P2 (n = 2; P 
< 0.05), P12 (n = 4; P < 0.001) and P161 (n = 3; P < 0.001) (Fig. 13A). In 
spite of low Cre expression levels postnatally, single IP injections of tamoxifen 
at P1 or P4 led to significant recombination in Fgf10iCre/+; Tomatoflox/+ lungs at 
P6 and P60 respectively (Fig. 13D-G; n = 4; penetrance = 100%). Induction in 
P1 Tomatoflox/+ pups (single transgenics) did not reveal any recombination at 
P10 (Fig. 13B, C; n = 2). Finally, serial tamoxifen IP injections (one daily 
injection for one week), followed by a ten-day tamoxifen diet and ten-day 
normal diet, revealed recombination in the trachea and lung of Fgf10iCre/+; 
Tomatoflox/+ adult mice (Fig. 13H, I; n = 3; penetrance = 100%). 
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Figure 13. Mismatch between Cre and Fgf10 expression levels in Fgf10iCre/+ 
embryos. 
(A) Fgf10 and Cre relative mRNA levels as determined by qPCR. For RNA 
preparation, whole embryos were used at E11.5 (n = 5) and E13.5 (n = 3) whereas 
lungs were used at E18.5 (n = 7), P2 (n = 2), P12 (n = 4) and P161 (n = 3). Fgf10 
expression levels increase throughout development and are maintained postnatally 
while Cre levels slowly increase throughout development and are minimal 
postnatally. (B) Induction in P1 Tomatoflox/+ pups reveals no recombination at P10 in 
the lung (n = 2). The area in the dotted box is magnified in (C). Inset in C shows 
high magnification with unlabeled cells. (D-G; n = 4) Induction in P1 and P4 
Fgf10iCre/+; Tomatoflox/+ pups reveals recombination at P6 and P60 in the lung 
respectively. Insets in E and G show high magnification with labeled cells. (H, I; n = 
3) Tamoxifen-induced recombination in lungs from Fgf10iCre/+; Tomatoflox/+ adult 
mice. Labeled cells are detected in the trachea and lung lobes. Inset in I shows 
high magnification with labeled cells. Data are shown as average values ± S.E.M. * 
P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Reference gene: β-actin. 
Tamoxifen-treated lungs were kindly provided by Dr. Denise Al Alam (CHLA, CA, 
USA). 
The 3 kb region downstream of Fgf10 transcriptional start site, which was 
deleted upon homologous recombination, was analyzed for putative 
regulatory elements by comparing transcription factor binding sites conserved 
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between mice and humans (using rVista, http://rvista.dcode.org). The analysis 
revealed the presence of several conserved transcription factor binding site-
dense regions (Fig. 14A). Interestingly, the 716 bp stretch at the 3’ end of the 
deleted region contains putative binding sites for SMAD4, NKX2.5, TBX5 and 
ISL1. Furthermore, the deleted region was analyzed for lung-related histone 
modifications using UCSC Genome Browser (http://genome.ucsc.edu). The 
analysis revealed the presence of a dense H3K4me3 (histone H3 
trimethylated at Lys4) modification site overlapping exon 1-intron 1 boundary 
(Fig. 14B). 
 
 
Figure 14. Bioinformatic screening for putative regulatory elements 3 kb 
downstream of Fgf10 ATG. 
(A) The screening reveals regions that are rich in transcription factor binding sites 
conserved between mice and humans (as predicted by rVista; 
http://rvista.dcode.org). Lung-related transcription factor binding sites within the 3’ 
end of the deleted sequence are shown. (B) Screening for lung-related H3K4me3 
modification sites (as predicted by UCSC Genome Browser; 
http://genome.ucsc.edu). A dense H3K4me3 modification site is predicted in the 
region overlapping exon 1-intron 1 boundary of Fgf10 gene. Abbreviations: ECRs: 
Evolutionary conserved regions; UTR: Untranslated region. 
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4.2. Fgf10-positive cells constitute a progenitor cell 
population during lung development and represent a 
subpopulation of resident mesenchymal stem cells during 
postnatal life 
4.2.1. Fgf10-positive cells are amplified and migrate during early lung 
development ex vivo 
In order to study the behavior of Fgf10-positive cells during the 
pseudoglandular stage of lung development, pregnant mice carrying 
Fgf10iCre/+; Tomatoflox/+ embryos received a single IP injection of tamoxifen at 
E11.5 and embryos were harvested at E12.5. Lungs were cultured in an air-
liquid interphase and bright field/fluorescence time-lapse imaging was carried 
out for 72 h (Fig. 15; n = 3). Lineage-labeled cells were originally detected as 
small populations in the distal mesenchyme and were mostly abundant in the 
accessory lobe (Fig. 15A, A’, A’’). During the first 24 h of culture, Tomato-
positive cells amplified exponentially and populated other regions of the 
growing lung (Fig. 15C, C’, C’’, I). At the end of the three-day culture, lineage-
labeled cells were highly abundant and dispersed throughout the lung 
mesenchyme (Fig. 15D, D’, D’’). After ex vivo culture, lungs were fixed, 
processed and stained for αSMA (Fig. 15E-H). An average of 81 ± 0.2 (n = 3) 
Tomato-positive cells was detected per 5 µm section (Fig. 15F, F’, J). A 
subpopulation of Fgf10-positive cells (5.67 ± 0.57 cells; n = 3) appeared in the 
PBSMC layer (Fig. 15H, H’, J). 
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Figure 15. Time-lapse imaging of E12.5 lungs from Fgf10iCre/+; Tomatoflox/+ 
embryos. 
Recombination was induced in vivo by a single IP injection of tamoxifen at E11.5. 
(A-D) Bright field imaging of the E12.5 lung undergoing branching morphogenesis. 
(A’-D’) Fluorescence imaging of Tomato-positive cells through the RFP channel 
showing the progressive amplification and migration of lineage labeled cells. Note 
the high Tomato expression in the accessory lobe. (A’’-D’’) Overlay of BF and 
fluorescent images. (E-H) Immunofluorescence detection of αSMA (green) in the 
Fgf10iCre/+; Tomatoflox/+ lung after 72 h of culture. The areas in white boxes are 
magnified in (E’-H’). A subpopulation of lineage-labeled cells lies in the 
parabronchial smooth muscle cell layer (white arrows in H’). (I) Quantification of the 
RFP signal over time. Lineage-labeled cells show exponential amplification during 
the first 24 h followed by linear amplification for the following two days. (J) 
Quantification of lineage-labeled cells after αSMA immunostaining. n = 3. Data are 
shown as average values ± S.E.M. Scale bars: (A-D) 500 µm; (E-H) 100 µm; (E’-H’) 
100 µm. BF: Bright field. 
4.2.2. Fgf10-positive cells are progenitors for parabronchial and vascular 
smooth muscle cells in vivo 
To study the commitment of Fgf10-positive cells to the smooth muscle lineage 
in vivo, pregnant mice carrying Fgf10iCre/+; Tomatoflox/+ embryos received a 
single IP injection of tamoxifen at E10.5 and embryonic lungs were harvested 
at E13.5, E15.5 and E18.5 (Fig. 16A-C). Because Tomato-positive cells were 
mostly abundant in the accessory lobe, this lobe was chosen for 
immunostaining. αSMA staining of Fgf10iCre/+; Tomatoflox/+ lungs revealed a 
subpopulation of Tomato-positive cells in the PBSMC layer at all three 
developmental stages (Fig. 16D-F). Among total Tomato-positive cells, 
Tomato-positive PBSMCs were significantly abundant at E13.5 (14.03 ± 
1.31% of total Tomato-positive cells; n = 3) (Fig. 16D, J) and E15.5 (18.47 ± 
3.75%; n = 3) (Fig. 16E, K) but declined at E18.5 (7.51 ± 0.72%; n = 3) (Fig. 
16F, L). Another population of Tomato-positive cells was identified in the 
vascular smooth muscle cell (VSMC) compartment at E15.5 (3.44 ± 0.96%; n 
= 3) (Fig. 16H, K) and E18.5 (4.88 ± 0.83%; n = 3) (Fig. 16I, L). A third 
population of lineage-labeled cells was observed in the vicinity of 
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parabronchial and vascular smooth muscle cells at all three stages (Fig. 16J-
L). These cells did not stain for the neuronal marker β-III Tubulin (data not 
shown). The various lineage-labeled cell populations, classified according to 
αSMA staining, are summarized in Table 7. 
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Figure 16. Contribution of Fgf10-positive cells labeled at E10.5 to the smooth 
muscle lineage in vivo. 
(A-C) Overlay of BF and fluorescent images of the lung at E13.5, E15.5 and E18.5. 
Note the strong RFP signal in the accessory lobe at all three stages (white arrows). 
(D-F) αSMA staining (green) on the accessory lobes of the lungs from the upper 
panel showing RFP+ cells in the PBSMC layer at all three stages (white arrows). 
The endogenous Tomato signal was detected via the RFP channel. (G) High 
magnification of αSma- RFP+ cells at E13.5. (H, I) αSMA staining showing RFP+ 
cells in the VSMC compartment at E15.5 and E18.5 (white arrows). (J-L) 
Quantification of multiple RFP+ populations based on αSMA staining. n = 3. Data 
are shown as average values ± S.E.M. Scale bars: (A) 500 µm; (B) 1000 µm; (C) 
750 µm; (D-I) 25 µm. 
 
Table 7. Classification of Fgf10-expressing cell populations labeled at E10.5 
according to αSma expression. 
Data are shown as average values ± S.E.M. Abbreviations: ND: Not determined; 
PBSMCs: Parabronchial smooth muscle cells; VSMCs: Vascular smooth muscle 
cells. 
 
Time of harvest E13.5 E15.5 E18.5 
Total RFP+ cells 
counted per sample 
278 ± 25 254 ± 33.84 392.33 ± 51.11 
% RFP+ PBSMCs 14.03 ± 1.31% 18.47 ± 3.75% 7.51 ± 0.72% 
% RFP+ VSMCs ND 3.44 ± 0.96% 4.88 ± 0.83% 
% RFP+ β-III Tub- 
cells around PBSMCs 
6.92 ± 0.56% 3.87 ± 1.72% 3.56 ± 0.12% 
% RFP+ β-III Tub- 
cells around VSMCs 
ND 1.45 ± 0.99% 3.86 ± 0.52% 
% other RFP+ cells 79.05 ± 1.20% 72.77 ± 7.32% 80.19 ± 0.38% 
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4.2.3. Fgf10-positive cells from early pseudoglandular stage are potent 
progenitors in vivo 
The genetic model used in this study revealed that only a minor proportion of 
Fgf10-positive cells commit to the smooth muscle lineage (Fig. 16J-L). Fgf10 
is known to be expressed by adipocyte precursors and Fgf10-null neonates 
suffer from impaired development of the white adipose tissue (Yamasaki et 
al., 1999; Sakaue et al., 2002). Thus, we decided to investigate whether 
Fgf10-positive cells give rise to an adipose-related cell lineage in the lung, the 
lipofibroblasts. Fgf10-positive cells were labeled during early pseudoglandular 
stage (E11.5) and lungs were harvested at E12.5, E15.5 and E18.5 (Fig. 17A-
C). Since lipofibroblasts start to emerge in the lung at E15.5 (Al Alam and El 
Agha, in progress), αSMA and ADRP immunostaining was performed at 
E18.5. For convenience, the left lung lobe was used to carry out 
immunofluorescence staining and quantification (Fig. 17D). An average of 450 
± 10.12 (n = 3) Tomato-positive cells was counted per sample and a minor 
proportion of RFP+ cells stained for αSMA around the epithelium (5.68 ± 
0.39%; n = 3) (Fig. 17E, F) and within vascular walls (4.31 ± 0.23%; n = 3) 
(Fig. 17E, G). Similarly to Fgf10-positive cells labeled at E10.5, a population 
of αSma- RFP+ cells was identified in the vicinity of PBSMCs (10.17 ± 0.88%; 
n = 3) (Fig. 17E, H) and VSMCs (3.92 ± 0.72%; n = 3) (Fig. 17E). These cells 
did not express the neuronal marker β-III Tubulin (Fig. S1). Interestingly, a 
significant population of RFP+ cells stained for ADRP (29.96 ± 5.17%; n = 3) 
(Fig. 17E, I). The remaining population of RFP+ cells (45.97 ± 4.2%; n = 3) 
that did not stain for αSMA or ADRP was characterized by its big size and the 
presence of filopodia (Fig. 17E, J, K). The lungs were also stained for other 
markers like CD45 and CD31 but no overlap was observed between these 
markers and the RFP signal (Fig. S1). 
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Figure 17. In vivo lineage tracing of Fgf10-positive cells labeled at E11.5. 
(A-C) Overlay of BF and fluorescent images of the lung at E12.5, E15.5 and E18.5. 
(D) Overlay of BF and fluorescent images of the left lung lobe at E18.5. (E) 
Quantification of RFP+ populations. (F-H) αSMA staining showing RFP+ cells in the 
PBSMC layer (F), vascular walls (G) and around PBSMCs (H). (I) 
Immunofluorescence staining showing Adrp+ RFP+ cells. (J) Big RFP+ cells with 
filopodia are present in the lung parenchyma. The area in the white box is 
magnified in (K). n = 3. Data are shown as average values ± S.E.M. Scale bars: (A) 
250 µm; (B,C) 1000 µm; (D) 500 µm; (F-K) 12.5 µm. 
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4.2.4. Fgf10-positive cells from late pseudoglandular stage are 
progenitors for lipofibroblasts in vivo 
Fgf10-positive cells from E11.5 showed to be precursor cells for PBSMCs, 
VSMCs and lipofibroblasts at E18.5 (Fig. 17). However, the commitment of 
these early progenitors to the smooth muscle lineage showed a decline 
beyond E15.5 (Fig. 16J-L). To further investigate this observation and to test 
whether lipofibroblast progenitors are restricted to early developmental 
stages, Fgf10-positive cells were labeled at E15.5 and embryonic lungs were 
harvested at E16.5 and E18.5 (Fig. 18). RFP expression was low at E16.5 
(Fig. 18A; n = 3) and was more pronounced at E18.5 (Fig. 18B). The left lung 
lobe was used to carry out immunofluorescence staining and quantification 
(Fig. 18D). An average of 499 ± 71.04 (n = 3) Tomato-positive cells was 
counted per sample at E18.5. αSMA staining showed minimal overlap with the 
RFP signal in the parabronchial (0.26 ± 0.03%; n = 3) and vascular (0.75 ± 
0.34%; n = 3) compartments (Fig. 18E). Significant numbers of αSma- RFP+ 
cells around PBSMCs (10.33 ± 1.65%; n = 3) (Fig. 18E, F) and VSMCs (4.99 
± 0.32%; n = 3) (Fig. 18E, G) were detected. ADRP staining revealed a 
considerable proportion of Adrp+ RFP+ cells (39.98 ± 8.28%; n = 3) (Fig. 18E, 
H, I). Similarly to cells labeled at E11.5, αSma- Adrp- β-III Tub- CD45- CD31- 
cells (43.69 ± 8.32%; n = 3) were also observed (Fig. 18E, J, K and Fig. S2). 
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Figure 18. In vivo lineage tracing of Fgf10-positive cells labeled at E15.5. 
(A,B) Overlay of BF and fluorescent images of the lung at E16.5 and E18.5. The 
RFP signal is more intense at E18.5. (C) Overlay of BF and fluorescent images of 
an E18.5 lung exposed to corn oil instead of tamoxifen. Note the absence of 
Tomato expression. (D) Overlay of BF and fluorescent images of the left lung lobe 
at E18.5. (E) Quantification of RFP+ populations. (F, G) αSMA staining showing 
αSma- RFP+ cells around PBSMCs (F) and VSMCs (G). (H) ADRP immunostaining 
showing RFP+ cells expressing Adrp. The area in the white box is magnified in (I). 
(J) Big RFP+ cells with filopodia are present in the lung parenchyma. The area in 
the white box is magnified in (K). n = 3. Data are shown as average values ± 
S.E.M. Scale bars: (A, D) 750 µm; (B, C) 1000 µm; (H, J) 25 µm; (I, K) 12.5 µm. 
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4.2.5. Fgf10 expression identifies lipofibroblast rather than alveolar 
myofibroblast progenitors during alveologenesis 
The alveolar stage of lung development is known for the prevalence of 
alveolar myofibroblasts. These cells, in addition to lipofibroblasts, are believed 
to play a critical role in secondary septa formation and alveolar maturation 
during postnatal alveolarization. To determine whether Fgf10-positive cells 
contribute to these lineages postnatally, pregnant mice carrying Fgf10iCre/+; 
Tomatoflox/+ embryos were left to develop to term and then fed tamoxifen-
containing pellets starting postnatal day 2 (P2). At P14, pups were sacrificed, 
lungs were harvested and processed, and the left lung lobe was used for 
immunostaining (Fig. 19). No Tomato signal was detected in lungs from 
Fgf10+/+; Tomatoflox/+ pups (Fig. 19A, L) whereas the signal was abundant in 
the Fgf10iCre/+; Tomatoflox/+ counterparts (Fig. 19B), especially near the main 
bronchus (Fig. 19C). An average of 141 ± 40 (n = 3) Tomato-positive cells 
was counted per Fgf10iCre/+; Tomatoflox/+ sample. αSMA immunostaining 
revealed a subpopulation of lineage-labeled cells expressing αSma (19.70 ± 
1.88%; n = 3) (Fig. 19D-H, M). These cells were located in the lung 
parenchyma and not at the tips of secondary septa where alveolar 
myofibroblasts are present. On the other hand, ADRP immunostaining 
showed that a major proportion of Fgf10-expressing cells gives rise to 
lipofibroblasts (67.74 ± 1.27%; n = 3) (Fig. 19I-K, M). 
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Figure 19. Fgf10-positive cells preferentially give rise to lipofibroblasts rather 
than alveolar myofibroblasts during alveologenesis. 
Nursing mother mice were fed tamoxifen-containing pellets from P2 to P14. (A) 
Whole-mount fluorescence imaging of the left lung lobe from an Fgf10+/+; 
Tomatoflox/+ pup. Note the absence of the Tomato signal. (B) Representative image 
of the left lung lobe from Fgf10iCre/+; Tomatoflox/+ pups. Note the strong Tomato 
signal around the mainstem bronchus. The area in the dotted box is magnified in 
(C). (D) Immunostaining for αSMA showing an αSma- RFP+ cell. The area in the 
dotted box is magnified in (E). The asterisks mark alveolar myofibroblasts in the 
secondary septa. (F) Immunostaining for αSMA showing an αSma+ RFP+ cell (white 
arrow). The area in the dotted box is magnified in (G). (H) Single-channel 
fluorescent images of the αSma+ RFP+ cell shown in (G). (I) Immunostaining for 
ADRP showing an Adrp+ RFP+ cell. The area in the dotted box is magnified in (J). 
(K) Single-channel fluorescent images of the Adrp+ RFP+ cell shown in (J). (L) 
Immunostaining for αSMA on an Fgf10+/+; Tomatoflox/+ lung. Note the absence of the 
Tomato signal. (M) Quantification of lineage-labeled cells according to αSma and 
Adrp expression. n = 3. Data are shown as average values ± S.E.M. Scale bars: (A, 
B) 2.5 mm; (C) 750 µm; (D-L) 25 µm. 
4.2.6. Fgf10-positive cells express resident MSC markers 
Fgf10-expressing cells were labeled at E11.5 or E15.5 and lungs were 
harvested at E18.5. Lungs were dissociated into single cell suspensions and 
stained for CD45, CD31, EpCAM, PDGFRα, c-Kit and Sca-1. 50,000-100,000 
cells were analyzed per sample per timepoint using a FACSAria III cell sorter 
(Fig. 20).  
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Figure 20. Flow cytometry analysis of Fgf10-positive cells labeled during 
embryonic development or postnatally. 
(A) E18.5 lungs from Fgf10+/+; Tomatoflox/+ embryos show no Tomato signal. (B, C) 
Tomato-positive cells account for ~0.5 and ~1.5% of the total E18.5 lung 
suspension when labeled at E11.5 and E15.5 respectively. (D) RT-PCR and 
immunostaining of sorted Fgf10-positive cells (labeled at E15.5) showing high 
expression of Adrp (white arrows). Note the presence of Adrp- cells (asterisk). Wild 
type E18.5 lungs were used as negative and positive controls for RFP and Adrp 
expression respectively. (E, F) 99.6% of Fgf10-expressing cells labeled at E11.5 
coexpress low levels of Sca-1 (Sca-1low) and 0.7% of these cells coexpress EpCam. 
9.9 and 7.3% of lineage-labeled cells express Pdgfrα and c-Kit respectively. (G, H) 
99.3% of Fgf10-expressing cells labeled at E15.5 coexpress low levels of Sca-1 
(Sca-1low) and 18.1% of these cells coexpress EpCam. 17.5% of these cells 
coexpress Pdgfrα and very little overlap with c-Kit expression is detected (1.4%). (I) 
Lungs from Fgf10+/+; Tomatoflox/+ adult mice show no Tomato signal. (J) Tomato-
positive cells account for ~0.1% of the total adult lung. (K) 15.7 and 22.8% of 
lineage-labeled cells coexpress EpCam and Sca-1 respectively. (L) A 
subpopulation of Fgf10-expressing cells (10.5%) shows the molecular signature of 
resident MSCs (CD45- CD31- Sca-1+). (M) Summary of the flow cytometry analysis 
of Fgf10-expressing cells during embryonic lung development and postnatally. (N) 
Section of an E15.5 Fgf10iCre/+; Tomatoflox/+ lung (labeled at E11.5) showing Pdgfrα 
expression. White arrows indicate RFP+ Pdgfrα+ cells and the dashed line marks 
the epithelial-mesenchymal boundary. n ≥ 2. Scale bars: (D) 25 µm; (N) 12.5 µm. 
No Tomato signal was detected in lungs from Fgf10+/+; Tomatoflox/+ embryos 
(Fig. 20A). Whereas lineage-labeled cells from E11.5 accounted for ~0.5% of 
the total lung, those from E15.5 accounted for ~1.5% (Fig. 20B, C). Most 
Fgf10-positive cells from E11.5 and E15.5 were CD45- CD31- (data not 
shown). A subpopulation of Fgf10-positive cells from E11.5 and E15.5 also 
expressed the mesenchymal marker Pdgfrα at E18.5 (9.9 and 17.5% 
respectively) (Fig. 20F, H). Interestingly, almost no Tomato-positive cells from 
E11.5 and 18.1% from E15.5 stained for the pan-epithelial cell marker EpCam 
at E18.5 (Fig. 20E, G). c-Kit expression was very low at this stage (E18.5) but 
staining revealed 7.3 and 1.4% overlap with the Tomato signal in E11.5 and 
E15.5 timepoints respectively (Fig. 20F, H). Almost all lineage-labeled cells 
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from both timepoints expressed low levels of Sca-1 (Sca-1low) at E18.5 (Fig. 
20E, G). RT-PCR and cytospin analysis of sorted Fgf10-positive cells (labeled 
at E15.5) showed high expression of Adrp (Fig. 20D), confirming the 
immunofluorescence data obtained from processed lung tissues (Figs. 17 and 
18). Histological analysis of E15.5 Fgf10iCre/+; Tomatoflox/+ lungs (labeled at 
E11.5) showed a sub-population of RFP+ Pdgfrα+ cells (Fig. 20N). 
Fgf10-expressing cells, labeled postnatally, represented ~0.1% of the total 
lung (a total of one million cells was analyzed) (Fig. 20J). 15.7 and 22.8% of 
RFP+ cells stained for EpCAM and Sca-1 respectively (Fig 6K). A 
subpopulation (10.5%) of the total RFP+ population exhibited the molecular 
signature of resident MSCs (CD45- CD31- Sca-1+) (Fig. 20L). 
4.2.7. Fgf10-expressing cells acquire myofibroblast characteristics 
during lung fibrosis 
In order to study the role of Fgf10-positive progenitor cells in lung repair 
postnatally, four week-old Fgf10iCre/+; Tomatoflox/+ female mice were fed 
tamoxifen-containing pellets for four weeks and then received an IT injection 
of saline or bleomycin (3.5 U/Kg of body weight). Fourteen days later, mice 
were anesthetized and lung function measurement was performed. Lung 
fibrosis was confirmed in bleomycin-treated animals by deteriorated lung 
function parameters (decrease in compliance and increase in elastance and 
resistance) compared to saline-treated animals (Fig. 21F; n = 3). H/E staining 
revealed the presence of dense fibrotic lesions in bleomycin-treated lungs 
compared to their saline counterparts (Fig. 21C, D). Interestingly, a three-fold 
increase in the number of Fgf10-expressing cells was detected in fibrotic 
lungs compared to control lungs (185 ± 27.54 vs 60 ± 9.81; n = 3) (Fig. 21A, 
B, E). 
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Figure 21. Fgf10-positive cells are amplified in bleomycin-treated lungs. 
(A, B) Whole-mount fluorescence imaging of the left lobes from saline and 
bleomycin-treated Fgf10iCre/+; Tomatoflox/+ lungs. High magnification images are 
shown in the insets. (C, D) H/E staining showing dense fibrotic lesions in 
bleomycin-treated lungs compared to saline-treated lungs. (E) Quantification of 
lineage-labeled cells in fibrotic and control lungs. (F) Lung function measurements 
confirming the presence of lung fibrosis in bleomycin-treated animals. n = 3. Data 
are shown as average values ± S.E.M. * P < 0.05; *** P < 0.001. Scale bars: (A, B) 
2.5 cm; (C, D) 50 µm. Abbreviations: BLM: Bleomycin; SAL: Saline. 
The lungs from saline and bleomycin-treated mice were immunostained for 
αSMA. Whereas none of the lineage-labeled cells stained for the 
myofibroblast marker in the saline group (Fig. 22A-C, G), 70.55 ± 2.86% (n = 
3) of Fgf10-expressing cells stained for αSMA in bleomycin-treated lungs (Fig. 
22D-G). Analysis of gene expression from bleomycin-treated lungs (day 14) 
showed an upregulation of myofibroblast markers (αSma and Col1a1) and a 
downregulation of lipofibroblast markers (Adrp, Lipase and Pparg) (Fig. 22H). 
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qPCR on biopsies from end-stage IPF patients also revealed a 
downregulation of lipofibroblast markers (CEBPa, PPARg, Lipase and 
Resistin) compared to donor biopsies (Fig. 22I). 
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Figure 22. Fgf10-positive cells give rise to activated myofibroblasts in 
bleomycin-induced pulmonary fibrosis. 
(A-C) A panel of representative images of lineage-labeled cells from saline-treated 
lungs. Note the absence of any overlap with the αSMA signal. (D-F) A panel of 
representative images of lineage-labeled cells from bleomycin-treated lungs. Note 
the overlap between the RFP and αSMA signals (white arrows). (G) Quantification 
of lineage-labeled myofibroblasts (n = 3). (H) qPCR analysis showing upregulation 
of myofibroblast markers (αSma and Col1a1) and downregulation of lipofibroblast 
markers (Adrp, Lipase and Pparg) in bleomycin-treated lungs (3 ≤ n ≤ 6) compared 
to saline-treated lungs (3 ≤ n ≤ 8). (I) qPCR analysis showing downregulation of 
lipofibroblast markers (CEBPa, PPARg, Lipase and Resistin) in end-stage IPF 
patients (6 ≤ n ≤ 8) compared to donors (n = 4 or 5). Data are shown as average 
values ± S.E.M. * P < 0.05. Reference genes: Hprt and PBGD. Scale bar: 10 µm. 
Abbreviations: IPF: Idiopathic pulmonary fibrosis; LIF: Lipofibroblasts; MYF: 
Myofibroblasts. cDNA from saline and bleomycin-treated lungs was kindly provided 
by Dr. Melanie Königshoff. 
4.3. Role of Fgf10 in lipofibroblast formation in vivo and in 
vitro 
4.3.1. Decreased Fgf10 expression correlates with decreased 
lipofibroblast formation in vivo 
Our lineage tracing data demonstrate that Fgf10-expressing cells are both 
early and late progenitors for lipofibroblasts in vivo. To test whether Fgf10 
expression levels are critical for the formation of the lipofibroblast lineage, we 
crossed Fgf10iCre mice with the previously described Fgf10-LacZ mice and 
pups were examined at P0. The resulting allelic combination of Fgf10-
LacZ/iCre yields hypomorphic levels of Fgf10 expression. Fgf10-LacZ/iCre 
pups were significantly smaller in size than their control littermates (Fgf10-
LacZ/+) and their hindlimbs were severely truncated (Fig. 23A vs. C). Fgf10-
LacZ/iCre lungs were smaller (Fig. 23B vs. D) and displayed thicker 
intersaccular walls as well as hemorrhagic areas upon histological analysis 
(Fig. 23E-H). Immunofluorescence for ADRP showed that mutant lungs 
exhibit impaired lipofibroblast formation as shown by decreased staining in the 
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mutants compared to the controls (Fig. 23I-L). In addition, gene expression 
analysis revealed an 80% decrease in Fgf10 expression in hypomorphic lungs 
compared to their littermate controls (Fig. 23M; n = 3; P < 0.01). The decrease 
in Fgf10 expression also correlated with a significant reduction in the 
expression levels of AEC II marker Sftpc (Fig. 23M; n = 3; P < 0.01) and 
endothelial cell marker Flk1 (Fig. 23M; n = 3; P < 0.01). Interestingly, αSma 
expression was significantly upregulated in hypomorphic lungs compared to 
control lungs (Fig. 23M; n = 3; P < 0.05). The expression levels of 
lipofibroblast markers were also validated at the RNA level (Fig. 23N). Zinc 
finger protein 423 (Zfp423) (marker for committed pre-adipocytes) (n = 3; P = 
0.0953), Cebpb (n = 3; P < 0.05) and Pparg (n = 3; P < 0.05) (markers for 
differentiating adipocytes) as well as Adrp (n = 3; P < 0.01) and Lipase (n = 3; 
P < 0.01) (markers for mature lipofibroblasts) showed a drastic decrease in 
mutant lungs compared to control lungs. 
 
 
 
 
 
 
 
 
 
 
 
 
Results                                                                                                            69 
 
 
 
 
 
Results                                                                                                            70 
 
Figure 23. Fgf10 dosage is critical for lipofibroblast formation in vivo. 
(A-D) Fgf10-LacZ/iCre pups are smaller in size compared to Fgf10-LacZ/+ control 
pups. Note the severe truncation of the hindlimbs (white arrows) as well as the 
hypoplastic lungs from the hypomorphic pups. (E-H) H/E staining of control and 
hypomorphic lungs. Note the thickening of intersaccular walls (black arrows) and 
hemorrhagic areas (white asterisk) in the mutant lungs. (I-L) ADRP immunostaining 
showing decreased Adrp expression in hypomorphic lungs compared to their 
control counterparts. (M) qPCR analysis showing significant downregulation of 
Fgf10, Sftpc and Flk1 as well as upregulation of αSma in hypomorphic lungs 
compared to littermate controls. (N) qPCR analysis showing significant 
downregulation of markers of adipocyte precursors as well as mature 
lipofibroblasts. n = 3. Data are shown as average values ± S.E.M. * P < 0.05; ** P < 
0.01. Reference gene: Hprt. Scale bars: (E, G) 500 µm; (F, H, I, K) 50 µm; (J, L) 25 
µm. 
4.3.2. FGF10 acts on embryonic mesenchymal cells and induces the 
expression of lipofibroblast markers in vitro 
FGF10 has so far been believed to signal only to the epithelium expressing 
FGFR2b. However, the contribution of Fgf10-positive cells to various 
mesenchymal lineages raised the question whether FGF10 can also signal to 
mesenchymal cells in the developing lung. To address this issue, primary 
culture of E19.5 rat lung mesenchyme was prepared and treated with 
rhFGF10. P-ERK and αSMA immunostaining revealed that embryonic lung 
fibroblasts respond to exogenous FGF10 by activating the MAPK/ERK 
pathway and downregulating αSma expression (Fig. 24A, B). Western blotting 
revealed that treatment with increasing concentrations of rhFGF10 resulted in 
increased expression of PTHrP receptor, PPARγ, C/EBPα and Leptin (Fig. 
24C). 
In order to determine whether FGF10 signaling in the mesenchyme triggers 
lipofibroblast formation in human fibroblasts, we used the well-established 
embryonic human lung fibroblast cell line WI-38. Treatment of these cells with 
increasing concentrations of rhFGF10 triggered the expression of 
lipofibroblast markers PPARγ, Leptin and C/EBPα (Fig. 24D). RT-PCR 
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revealed that WI-38 cells and rat lung fibroblasts (Passage 3) express Fgfr1b 
rather than Fgfr2b while rat lung fibroblasts (Passage 1) express Fgfr1b as 
well as Fgfr2b (Fig. 24E). Sorted Fgf10-positive cells (labeled at E14.5) from 
E18.5 embryonic mouse lungs were also treated with rhFGF10. The treatment 
resulted in the activation of the MAPK/ERK pathway (Fig. 24F, G). RT-PCR 
showed that these cells express Fgfr1b rather than Fgfr2b similarly to rat lung 
fibroblasts (Passage 3) and WI-38 cell line. These cells showed to also 
express low levels of Fgfr1/2c (Fig. 24H). 
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Figure 24. Embryonic lung fibroblasts respond to exogenous FGF10 and 
upregulate lipofibroblast markers in vitro. 
(A-B) Immunofluorescence staining for αSMA and P-ERK showing activation of the 
MAPK/ERK pathway and downregulation of αSma expression in rhFGF10-treated 
embryonic rat lung fibroblasts. (C) Western blots showing upregulation of 
lipofibroblast markers (PTHrP receptor, PPARγ, C/EBPα and Leptin) upon 
treatment with increasing concentrations of rhFGF10. GAPDH was used as a 
loading control. (D) Western blots showing upregulation of lipofibroblast markers 
(PPARγ, Leptin and C/EBPα) in WI-38 cells upon treatment with rhFGF10. (E) RT-
PCR showing that WI-38 cells and embryonic rat lung fibroblasts (Passage 3) 
express Fgfr1b rather than Fgfr2b. Passage 1 embryonic rat lung fibroblasts 
express both Fgfr1b and Fgfr2b. E18.5 mouse lung homogenates were used as a 
positive control. (F, G) Sorted Fgf10-positive cells respond to rhFGF10 treatment by 
activation of MAPK/ERK pathway. (H) RT-PCR showing that Fgf10-positive cells 
express Fgfr1b rather than Fgfr2b as well as low levels of Fgfr1/2c. MLE-15 cells 
and E18.5 lungs were used as controls for the expression of epithelial and 
mesenchymal isoforms of Fgfr1/2. Data were kindly provided by Drs. Virender K. 
Rehan (UCLA, CA, USA) and Denise Al Alam (CHLA, CA, USA). 
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5. Discussion 
5.1. Validation of Fgf10iCre knock-in mouse line 
FGF10 is a morphogen that is critical for the embryonic development of many 
organs including the lung, duodenum, cecum, colon, pancreas, limb and 
mammary placodes. Fgf10 knockout mice suffer from agenesis of the 
corresponding organs, thus limiting any real use of these mice in studying the 
behavior or lineage commitment of Fgf10-positive cells. On the other hand, 
due to the stability of β-galactosidase, the Fgf10-LacZ transgenic line allows 
non-inducible transient tracing of Fgf10-positive cells in many organs. 
However, the gold standard for an optimal lineage tracing tool relies on the 
inducibility of constitutive cell labeling via the controlled activation of Cre 
recombinase. Then, short- and long-term lineage commitment can be 
investigated. Therefore, the data obtained with the Fgf10-LacZ line should 
always be validated using the proper Cre inducible line. Nevertheless, this line 
has helped identify the progeny of Fgf10-positive cells in the heart, lung, gut, 
mammary glands, brain (Kelly et al., 2001; Mailleux et al., 2005; Veltmaat et 
al., 2006; Ramasamy et al., 2007; Hajihosseini et al., 2008; Parsa et al., 2008) 
and limbs (Hajihosseini and Bellusci, unpublished results). Thus, the Fgf10iCre 
knock-in line represents a novel tool that bypasses the pitfalls associated with 
the Fgf10-LacZ transgenic line. This is because Fgf10-positive cells are 
exclusively labeled upon tamoxifen injection, after which labeled cells can be 
traced and characterized. A previous report has shown that intraperitoneally 
administered tamoxifen reaches effective levels in the embryonic circulation 
within 12 hours, after which it is cleared from the pregnant mouse within 12 
hours (Nakamura et al., 2006). This 24-hour time frame allows accurate 
labeling of Fgf10-positive cells. 
In the first part of this study, we induced recombination in pregnant females 
carrying Fgf10iCre/+; Tomatoflox/+ embryos at E15.5. At E18.5, lineage-labeled 
cells were found in the ears of the embryos (Fig. 10A”) and this observation is 
consistent with previously published reports that describe the role of FGF10 in 
inner ear formation (Alvarez et al., 2003). Moreover, labeled cells were 
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observed in the skin (Fig. 10B”) where FGF10 is known to be expressed in the 
dermal papillae (Hamada et al., 1999). In the lung, labeled cells were 
dispersed throughout the mesenchyme (Fig. 11A’). However, the signal was 
more pronounced in interlobular septa (Fig. 11B’). Further studies need to be 
performed in order to explain this observation. As for the trachea, labeled cells 
were arranged in discrete ring-like structures (Fig. 11C’). This pattern is 
consistent with previously published reports about the role of FGF10 in 
tracheal cartilage ring formation in mice (Tiozzo et al., 2009; Sala et al., 
2011). We also used Fgf10-LacZ lungs from the same stage (E18.5) to 
validate our data. As expected, X-Gal staining of Fgf10-LacZ lungs revealed 
similar sites of Fgf10 expression (Fig. 11A’’-C’’). 
For functional inactivation studies, we generated E14.5 Fgf10iCre/flox; 
Tomatoflox/+ embryos in which Cre had been activated since E8.5. By virtue of 
the embedded Tomatoflox reporter, we were able to locate recombination sites 
and thus, we restricted our diagnostic to those specific sites. An abnormal 
phenotype, characterized by webbing of the digits, was observed in the 
forelimbs (Fig. 12H vs. E, M). This finding agrees with previous reports about 
the involvement of Fgf10 misregulation in digit abnormalities such as 
syndactyly [(Liu et al., 2002); (Al Alam and Bellusci, in revision)]. Moreover, 
Fgf10iCre/flox; Tomatoflox/+ lungs showed clear developmental abnormalities 
characterized by a deformed shape as well as branching simplification (Fig. 
12C vs. B, G vs. F, J). This phenotype is similar to that obtained by Abler et 
al. who used a general mesenchymal driver line (Dermo1Cre) to perform 
conditional gene inactivation of Fgf10 (Abler et al., 2009). Last but not least, 
our research group has previously demonstrated that the gut is a major site of 
Fgf10 expression and that Fgf10-null embryos suffered from cecal atresia. 
Our data agrees with this finding as Fgf10iCre/flox; Tomatoflox/+ embryos suffered 
from a hypomorph-like phenotype at the level of the cecum upon partial loss 
of function of Fgf10 (Fig. 12L vs. I, K). 
One drawback of the Fgf10iCre line is the mismatch between Cre and Fgf10 
expression levels as examined at different developmental stages by qPCR 
(Fig. 13A). To understand the inefficient expression of Cre from the Fgf10iCre 
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locus, we performed a bioinformatic analysis for the 3 kb deleted sequence 
downstream of ATG codon of exon 1 of Fgf10 gene using online tools (Fig. 
14). The analysis revealed the presence of H3K4me3 site overlapping exon 1-
intron 1 boundary. This histone modification is known to be associated with 
the 5’ end of actively transcribed genes (Santos-Rosa et al., 2002). On the 
other hand, several conserved binding sites for lung-related transcription 
factors were detected, including binding sites for SMAD4, NKX2.5, TBX5 and 
ISL1. TBX5 is thought to directly control Fgf10 expression in the lung 
mesenchyme (Cebra-Thomas et al., 2003). Moreover, a recent report has 
shown that ISL1 regulates FGF10 transcription within the second heart field 
by binding to an enhancer element in intron 1 of FGF10 gene (Golzio et al., 
2012). Altogether, these data suggest the presence of key regulatory 
elements in intron 1 critical for the maintenance of Fgf10 expression over 
time. Nonetheless, this line allows targeting a subset of Fgf10-positive cells 
after birth allowing to study the lineage commitment of these cells during 
homeostasis and during the repair process after injury. 
Alternative strategies that would bypass potential consequences on Cre 
expression levels include fusion of Cre-ERT2 in frame with the ATG codon of 
Fgf10 without deleting intronic sequences, thus preserving putative regulatory 
elements and matching Cre expression levels to endogenous Fgf10. Another 
approach would be the insertion of IRES-Cre-ERT2 in the 3' UTR downstream 
of Fgf10 stop codon. In this case, Fgf10 would still be expressed at 
physiological levels but Cre expression levels would depend greatly on the 
activity of the IRES element. 
In conclusion, the Fgf10iCre knock-in line described in this study is a novel tool 
that allows labeling and tracking of Fgf10-positive cells. The mosaic 
recombination pattern, as illustrated by the Tomatoflox reporter, makes this line 
convenient for clonal analysis, especially when a partial loss of function 
approach is desired. This tool can potentially bring insight on the role of 
Fgf10-positive progenitor cells in development and repair after injury. 
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5.2. Lineage tracing of Fgf10-positive progenitor cells during 
embryonic lung development 
The embryonic lung mesenchyme consists of cells that belong to distinct 
lineages including myogenic, adipogenic, chondrogenic, neuronal and other 
lineages. Most of these cell types arise from endogenous (or resident) 
progenitor populations while few (eg. nerve cells) arise from exogenous 
sources (the neural crest). Moreover, there is strong evidence suggesting that 
hematopoietic cells in the mesenchyme derive from non-bone marrow-derived 
resident progenitors (Lugus et al., 2009). Cell fate determination likely arises 
from a complex network of autocrine and paracrine signals leading to the 
proliferation and differentiation of lineage-restricted as well as multipotent 
progenitor cell populations. 
Most of the mesenchymal cell types that populate the lung start to emerge 
during early phases of embryonic lung development (Table 2). One of the 
early markers of the lung mesenchyme is Fgf10. During early lung 
development, Fgf10 is expressed in the distal (sub-mesothelial) mesenchyme 
and it acts on the opposite epithelium expressing Fgfr2b (Bellusci, Grindley, et 
al., 1997). Fgf10 maintains epithelial cells in a progenitor-like state and 
induces epithelial branching and migration. Loss of function of Fgf10 results in 
branching simplification and decreased numbers of epithelial progenitors. 
Although the primary target of FGF10 is the epithelium, severe mesenchymal 
abnormalilties are also observed when FGF10 signaling is attenuated 
(Ramasamy et al., 2007). 
Our research group has shown that Fgf10-expressing cells are highly dynamic 
and they relocate around the growing epithelial buds and give rise to PBSMCs 
on the proximal side of the epithelial tree (Mailleux et al., 2005). In the latter 
study, distal mesenchymal tissue from Fgf10-LacZ lungs was grafted into the 
corresponding position in wild type lungs and the lungs were allowed to grow 
ex vivo. LacZ-positive cells were eventually detected alongside the growing 
epithelium giving rise to PBSMCs. β-Catenin signaling was shown to control 
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the proliferation but not the differentiation of these PBSMC progenitors (De 
Langhe et al., 2008). 
The dynamic expression pattern of Fgf10 in the lung mesenchyme throughout 
development suggests that Fgf10-expressing cells behave differently at 
different developmental stages. Here, we used the Fgf10iCre knock-in mouse 
line, combined with the Tomatoflox reporter line, to permanently label Fgf10-
positive cells (as well as their descendants) and study their fate in a time-
controlled manner. Initially, cells were labeled at E11.5 and lungs were 
harvested at E12.5 (Fig. 15). Time-lapse imaging on intact embryonic lungs 
showed that Fgf10-expressing cells possess high mitotic and migratory 
capabilities. These cells, initially located in the distal mesenchyme, amplified 
and migrated greatly throughout the mesenchyme over the 72 h-culture 
period. However, it cannot be excluded that remaining traces of tamoxifen can 
also induce Cre activity, and thus RFP expression, ex vivo. In agreement with 
what our group has previously shown (Mailleux et al., 2005), a subpopulation 
of Fgf10-positive cells was eventually embedded within the PBSMC layer. 
Lineage tracing of Fgf10-positive cells from E10.5 showed that the smooth 
muscle program in these cells is mostly active between E11.5 and E15.5, 
beyond which the cells seem to commit to other lineages (Fig. 16). 
Interestingly, we show for the first time that these cells are also progenitors for 
VSMCs. Que et al. have previously shown that mesothelial Wt1-positive cells 
are progenitors for VSMCs but not PBSMCs (Que et al., 2008). Here, we 
provide evidence for the presence of an Fgf10-expressing progenitor cell 
population that is capable of generating both lineages. 
The domain of Fgf10 expression in the embryonic lung has been thoroughly 
studied. Northern blotting and qPCR data show that Fgf10 transcripts 
progressively accumulate in the embryonic lung between E11.5 and E18.5 
(Bellusci, Grindley, et al., 1997; El Agha et al., 2012). In situ hybridization and 
X-Gal staining of Fgf10-LacZ lungs show that Fgf10 expression is restricted to 
the tips of the distal mesenchyme until E14.5, after which the expression 
becomes dispersed throughout the mesenchyme (Mailleux et al., 2005; 
Ramasamy et al., 2007; El Agha et al., 2012; Tiozzo et al., 2012). Our lineage 
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tracing data reveal two distinct populations of progenitor cells, each of which 
is characterized by a distinct pattern in terms of cell localization as well as 
differentiation potential. When labeled at E11.5, these cells reside mostly in 
the distal mesenchyme at E18.5 (especially observed in the accessory lobe) 
and contribute to myogenic (PBSMCs and VSMCs) as well as adipogenic 
lineages (lipofibroblasts) (Fig. 17). On the contrary, Fgf10-positive cells are 
more dispersed at E18.5 when labeled at E15.5 and they give rise to 
adipogenic - but not myogenic – lineages (Fig. 18). An interesting 
subpopulation of αSma- RFP+ cells adjacent to parabronchial and vascular 
smooth muscle cells was observed in both progenitor populations. Initially, we 
thought that these cells could have a neuronal nature since Fgf10 is known to 
be involved in neurogenesis (Hajihosseini et al., 2008; Haan et al., 2013). 
However, β-III Tubulin immunostaining did not show any overlap with the 
lineage label (Figs. S1 and S2). The progenies of these two progenitor cell 
populations are summarized in Figure 25 and Table 8. 
 
 
Figure 25. Fgf10-positive cells from E11.5 and E15.5 represent two distinct 
populations of mesenchymal progenitors. 
Fgf10-positive cells labeled at E11.5 give rise to PBSMCs, VSMCs and 
lipofibroblasts at E18.5. Fgf10-positive cells labeled at E15.5 give rise to 
lipofibroblasts at E18.5. 
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Table 8. The differentiation potential of Fgf10-positive progenitor cells 
becomes progressively restricted during embryonic lung development. 
Comparison between the lineage commitment of Fgf10-positive cells when labeled 
at E11.5 and E15.5. Whereas both populations give rise to lipofibroblasts at E18.5, 
cells from E11.5 - but not E15.5 - give rise to PBSMCs and VSMCs in vivo. n = 3. 
 
 
Time of labeling E11.5 E15.5 P value 
A
n
a
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Total RFP+ cells 
counted per sample 
450 ± 10.12 499 ± 71.04 - 
% RFP+ PBSMCs 5.68 ± 0.39% 0.26 ± 0.03% 0.0002 
% RFP+ VSMCs 4.31 ± 0.23% 0.75 ± 0.34% 0.001 
% RFP+ β-III Tub- cells 
around PBSMCs 
10.17 ± 0.88% 10.33 ± 1.65% 0.9346 
% RFP+ β-III Tub- cells 
around VSMCs 
3.92 ± 0.72% 4.99 ± 0.32% 0.2436 
% RFP+ Lipofibroblasts 29.96 ± 5.17% 39.98 ± 8.28% 0.3629 
% other RFP+ cells 45.97 ± 4.2% 43.69 ± 8.32% 0.8192 
The role of Fgf10 in the formation of adipogenic lineages has already been 
demonstrated. Fgf10-null neonates suffer from impaired development of the 
white adipose tissue (Yamasaki et al., 1999; Sakaue et al., 2002). In vitro, 
Fgf10 is involved in the differentiation of pre-adipocytes to adipocytes. This is 
demonstrated by the ability of FGF10-blocking antibodies to inhibit insulin-
mediated adipogenesis in NIH3T3-L1 cells (Sakaue et al., 2002). Here, we 
show, for the first time, that Fgf10-expressing cells are precursor cells for 
lipofibroblasts in the embryonic and postnatal lung. We also generated the 
Fgf10-LacZ/iCre hypomorphic allele (equivalent to Fgf10-LacZ/- allele) and 
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the phenotype of the pups and lungs recapitulated what our group has 
previously published (Ramasamy et al., 2007). Moreover, we also show that 
hypomorphic Fgf10 newborns suffer from decreased lipofibroblast formation 
(Fig. 23). Interestingly, lungs from these pups reveal severe downregulation of 
early, intermediate and late markers of adipogenesis (Zfp423, Cebpb, Pparg, 
Adrp and Lipase), suggesting that Fgf10 dosage is critical not only for the 
formation of lipofibroblasts during late lung development but also for the 
maintenance of early lipofibroblast progenitors. Thus, we provide direct 
evidence for the involvement of Fgf10 in the formation of lipofibroblasts in the 
developing lung. We propose a model in which FGF10 is involved in 
amplifying committed pre-adipocytes (ZFP423+) and potentiating the 
differentiation process into mature adipocytes (Fig. 26). 
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Figure 26. Model for the involvement of FGF10 in adipogenesis. 
ZFP423 is a transcription factor that identifies committed pre-adipocytes (Gupta et 
al., 2012). During the differentiation of pre-adipocytes, C/EBPβ is upregulated  
followed by C/EBPα and PPARγ upregulation [Reviewed in (Rosen, 2005)]. The 
proposed model shows that FGF10 is involved in the amplification of committed 
pre-adipocytes (ZFP423+) and enhancing the differentiation from C/EBPβ+ cells, to 
C/EBPα+ and PPARγ+ cells and finally to mature adipocytes. ZFP423: Zinc finger 
protein 423. 
FGF10 has so far been believed to signal only to the epithelium expressing 
Fgfr2b. Here, we demonstrate that exogenous FGF10 acts on embryonic 
human and rodent fibroblasts to induce the lipofibroblast phenotype (Fig. 24). 
Thus, we demonstrate that paracrine FGF10 signaling triggers the formation 
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of lipofibroblasts in vitro. RT-PCR on mesenchymal cells showed that 
FGFR1b seems to mediate the action of exogenous FGF10 on these cells. 
In order to gain more insight into the expansion pattern of Fgf10-positive cells 
during embryonic development, cells were labeled at E11.5 or E18.5 and 
lineage-labeled cells were analyzed by FACS at E18.5. Whereas Fgf10-
positive cells labeled at E11.5 accounted for 0.5% of the total lung at E18.5, 
those labeled at E15.5 represented 1.5% of the total E18.5 lung (Fig. 20). This 
indicates that during embryonic lung development, not all Fgf10-expressing 
cells derive from Fgf10-positive mother cells; rather, the Fgf10-expressing 
domain expands by de novo induction of Fgf10-expression (Fig. 27). 
Moreover, flow cytometry analysis revealed that a minor subpopulation of 
early Fgf10-positive progenitors (labeled at E11.5) acquires Pdgfrα at later 
developmental stages. On the other hand, a subpopulation of late Fgf10-
positive progenitors (labeled at E15.5) acquires Pdgfrα as well as pan-
epithelial cell marker EpCam. Interestingly, both populations express low 
levels of Sca-1 (Sca-1low) at E18.5. 
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Figure 27. Model for the expansion of Fgf10-expressing cells during 
embryonic lung development. 
Cells labeled at E11.5 account for ~0.5% of the total lung at E18.5. At E15.5, Fgf10 
expression is induced in fibroblasts that do not derive from the original Fgf10-
expressing cell population. When tamoxifen is injected at E15.5, Fgf10-expressing 
cells, derived from the E11.5 Fgf10-positive ancestors, and Fgf10-expressing cells 
that start expressing Fgf10 at E15.5 are labeled. The combination of both lineages 
accounts for ~1.5% of the total lung at E18.5. 
5.3. The role of Fgf10-positive progenitor cells in lung 
homeostasis and repair during postnatal life 
5.3.1. Fgf10-positive cells during the alveolar stage of lung development 
Alveolar myofibroblasts and lipofibroblasts are two cell lineages that are highly 
abundant during postnatal alveolarization. These cell types play important 
roles in the formation of functional alveoli in newborns. Alveolar 
myofibroblasts (not to be confused with activated myofibroblasts that prevail in 
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lung fibrosis) are contractile αSma-expressing fibroblasts that reside at the 
tips of secondary septa. These cells produce an elastin precursor, 
tropoelastin. Elastin is required for initiation and progression of secondary 
septa formation (Vaccaro and Brody, 1978; Noguchi et al., 1989; Yamada et 
al., 2005). These cells transiently populate the lung during alveologenesis and 
are believed to undergo programmed cell death (or apoptosis) leading to their 
disappearance from the adult lung (Bruce et al., 1999). Fibroblasts expressing 
Pdgfrα (receptor for PDGF-A) are believed to be progenitors for alveolar 
myofibroblasts. Pdgfa-null newborns lack alveolar myofibroblasts and suffer 
from failure in alveolarization (Boström et al., 1996; Lindahl et al., 1997). 
On the other hand, lipofibroblasts are lipid-containing interstitial fibroblasts 
that are also involved in alveolar maturation. These cells supply AEC II with 
triglycerides that are required for the synthesis of pulmonary surfactant. AEC 
II secrete PTHrP that is critical for the induction and maintenance of the 
lipofibroblast phenotype through the PPARγ pathway. Disruption of PTHrP 
signaling leads to lipofibroblast-to-myofibroblast transdifferentiation and 
defective alveologenesis (Torday et al., 2003; Rubin et al., 2004; Torday and 
Rehan, 2007; Rehan and Torday, 2012). Although the number of 
lipofibroblasts peaks around two weeks of age, a significant number of these 
cells persists in the adult lung (Rehan et al., 2006). 
In this study, the contribution of Fgf10-positive progenitor cells to these two 
lineages was addressed. When labeled during the alveolar stage of lung 
development, most Fgf10-expressing cells gave rise to lipofibroblasts 
whereas a minor population gave rise to myofibroblasts (Fig. 19). These 
myofibroblasts did not localize at the tips of secondary septa where alveolar 
myofibroblasts are known to prevail. Yet, it has been shown that FGFR2b 
ligands are required for the differentiation of alveolar myofibroblast 
progenitors during homeostasis (Perl and Gale, 2009) as well as regeneration 
after pneumonectomy (Chen et al., 2012). Moreover, Ramasamy et al. have 
shown that Fgf10-hypomorphic lungs have impaired septation/alveolarization 
postnatally (Ramasamy et al., 2007). Thus, we conclude that although a minor 
population of Fgf10-expressing cells gives rise to αSma-positive fibroblasts, 
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Fgf10-positive cells are not progenitors for alveolar myofibroblasts in vivo. 
However, paracrine signaling between Fgf10-positive cells and Pdgfrα-
positive progenitors is likely necessary for the formation of the alveolar 
myofibroblast lineage during the alveolar stage of lung development. Our data 
suggest that alveolar myofibroblasts are unlikely to derive from Fgf10-
expressing lipofibroblasts during the first two weeks after birth. 
5.3.2. Fgf10-positive cells during homeostasis and disease 
Fgf10-positive cells were examined during lung homeostasis in the adult 
mouse. Despite the low efficiency of the Fgf10iCre line in labeling Fgf10-
expressing cells postnatally, FACS analysis of disaggregated adult lungs 
revealed that these cells constitute ~0.1% of the whole lung. A subpopulation 
of Fgf10-expressing cells (10.5% of total Fgf10-expressing cells) exhibits the 
molecular signature (CD45- CD31- Sca-1+) of resident MSCs that were 
previously described by McQualter et al. (McQualter et al., 2009) (Fig. 20). In 
the latter study, the authors reported that the CD45- CD31- Sca-1+ fraction of 
the adult lung represents a mesenchymal population of resident progenitor 
cells. These cells have shown to be precursors for myogenic and adipogenic 
lineages and are also critical for the growth of epithelial progenitors in vitro, 
likely via the FGF10/FGFR2b signaling pathway (McQualter et al., 2009, 
2010). In their co-culture system, McQualter et al. have demonstrated that 
mesenchymal progenitors relocate around epithelial colonies giving rise to 
SMCs, thus recapitulating the behavior of Fgf10-expressing cells during 
embryonic lung development (Mailleux et al., 2005). Thus, our data support 
the findings of McQualter et al. and provide direct evidence that Fgf10 
expression identifies a subset of resident MSCs postnatally. 
In order to study the role of Fgf10-positive progenitor cells in lung repair after 
injury, Fgf10iCre/+; Tomatoflox/+ adult mice were fed tamoxifen-containing pellets 
before bleomycin was delivered intratracheally. After fourteen days, mice 
were anesthetized and lung function was measured. Lung function 
parameters on anesthetized animals and histology of the corresponding lungs 
confirmed the presence of lung fibrosis in bleomycin-treated mice compared 
to saline-treated controls. Interestingly, a three-fold increase in the number of 
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lineage-labeled cells was observed in bleomycin-challenged lungs (Fig. 21). 
Whereas the Fgf10-expressing pool did not contribute to αSma-positive 
fibroblasts under homeostatic conditions, most of lineage-labeled cells 
expressed αSma in bleomycin-treated lungs (Fig. 22). 
Activated myofibroblasts are thought to arise from resident fibroblasts, 
circulating fibrocytes and AEC II by EMT during lung fibrosis. Recently, 
resident fibroblasts have shown to be the main repertoire for these cells. Rock 
et al. have demonstrated that activated myofibroblasts arise from multiple 
fibroblastic populations and that pericyte-like cells were abundant in fibrotic 
lesions but failed to express high levels of αSma (Rock et al., 2011). Hoyles et 
al. have demonstrated that knocking down high affinity type II TGF-β 
receptors in resident fibroblasts prevents their differentiation to activated 
myofibroblasts, resulting in attenuation of lung fibrosis (Hoyles et al., 2011). In 
this study, we show that Fgf10-positive progenitor cells are a source of 
activated myofibroblasts in bleomycin-induced pulmonary fibrosis. Gene 
expression analysis on bleomycin-treated lungs showed an upregulation of 
myofibroblast markers that also correlated with a downregulation of 
lipofibroblast markers compared to saline-treated lungs (Fig. 22). This 
suggests that these cells undergo lipofibroblast-to-myofibroblast 
transdifferentiation. Gene expression analysis on biopsies from end-stage IPF 
patients also showed a downregulation in lipofibroblast markers compared to 
donors, suggesting that this transdifferentiation is likely to occur during lung 
fibrosis in humans. 
Lipofibroblast-to-myofibroblast transdifferentiation has already been 
demonstrated in the hyperoxia model of Bronchopulmonary dysplasia (BPD). 
Rehan and Torday have shown that fetal rat lung fibroblasts lose their 
adipogenic phenotype and transdifferentiate to myofibroblasts when exposed 
to hyperoxia in vitro (Rehan and Torday, 2003). It is also believed that injury 
to AEC II disrupts PTHrP signaling and causes neighboring fibroblasts to 
default to the myofibroblast phenotype (Torday and Rehan, 2007). TGF-β has 
also shown to induce subcutaneous adipocyte-to-myofibroblast differentiaton 
in skin fibrosis. Wnt signaling, particularly via Wnt3a ligand, is suggested to 
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mediate TGF-β-induced mesenchymal fibrogenic responses and loss of 
adipose tissue in skin fibrosis (Akhmetshina et al., 2012; Wei et al., 2012). 
Similarly, there is evidence suggesting that functional Wnt signaling is 
increased in injured epithelial cells as well as fibrotic foci in IPF (Chilosi et al., 
2003; Königshoff et al., 2008). On the other hand, the ability of PPARγ 
agonists (eg. Rosiglitazone) to attenuate TGF-β-mediated fibrosis has been 
demonstrated in vitro (Burgess et al., 2005) and in vivo (Genovese et al., 
2005; Wu et al., 2009; Jin et al., 2012). 
Our research group has previously shown that Fgf10 overexpression in AEC II 
is preventive and therapeutic against bleomycin-induced pulmonary fibrosis in 
mice. Analysis of the Bronchoalveolar lavage fluid (BALF) from those mice 
revealed a decrease in the levels of endogenous bioactive TGF-β1. Tunel 
assays showed increased survival of AEC II despite bleomycin administration 
(Gupte et al., 2009). 
Thus, we conclude that under homeostatic conditions, Fgf10-expressing cells 
give rise to lipofibroblasts in the lung. During pulmonary fibrosis, these cells 
transdifferentiate to activated myofibroblasts. Treatment with FGF10 could 
help reverse the transdifferentiation and restore the lipofibroblast phenotype. 
5.4. Future perspectives and stem cell therapy in regenerative 
medicine 
The use of recombinant human FGFs, produced in Escherichia coli (E. coli), 
to treat human diseases has already been implemented more than a decade 
ago. Palifermin (trade name Kepivance®, Amgen Inc., CA, USA) contains a 
truncated form of human Keratinocyte growth factor (KGF or FGF7) and is 
used to treat and prevent oral mucositis (mouth sores) and dysphagia 
(difficulty in swallowing) in hematologic cancer patients undergoing severe 
chemotherapy and radiation therapy prior to bone marrow transplantation 
(FDA approval in 2004). Palifermin is introduced intravenously and helps to 
regenerate the mucosal barrier. Palifermin has also shown to induce alveolar 
maintenance programs in elastase-induced emphysema in mice (Yildirim et 
al., 2010). 
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On the other hand, Repifermin contains a truncated form of KGF2 (or FGF10) 
and was developed by Human Genome Sciences (Rockville, MD, USA) and 
GlaxoSmithKline (London, UK) to treat wounds, oral and intestinal mucositis 
and inflammatory bowel diseases (Wheeler, 2001). Repifermin has shown to 
accelerate healing of skin wounds (Soler et al., 1999) and colitis (Meerveld et 
al., 2003) in animals as well as healing of chronic venous ulcers in humans 
(Robson et al., 2001). However, it did not show to be effective in treating 
active ulcerative colitis in clinical trials (Sandborn et al., 2003) and thus, the 
development of this drug was ceased in 2004. Yet, attempts to enhance its 
unfolding temperature (Derrick et al., 2007) and ensure sustained release 
(Huang and Berkland, 2009) have shown to significantly increase the 
bioavailability and efficiency of Repifermin. This suggests that this drug could 
be revived and possibly tested in lung regeneration after injury. 
To date, Pirfenidone (InterMune Inc., Brisbane, CA, USA) is the only available 
drug that is prescribed for treating IPF patients. Although it was implemented 
in clinical trials fourteen years ago, the mechanism of action for Pirfenidone is 
still unknown. Unfortunately, clinical trials have shown that the effects of 
Pirfenidone on IPF patients are subtle in terms of improving quality of life, 
symptoms and survival [Reviewed in (Jenkins, 2013; Raghu and Thickett, 
2013)]. 
On the other hand, the use of stem cells in regenerative medicine seems to 
be promising. Isolation of MSCs was first reported in 1976 and these cells 
were described as an adherent, clonogenic, non-phagocytic and fibroblastic-
like population of bone marrow cells (Friedenstein et al., 1976). MSCs not 
only give rise to multiple mesenchymal and non-mesenchymal lineages, but 
also have immunomodulatory properties which makes them a good candidate 
for regenerative medicine as their allogeneic transplantation bypasses host 
immune rejection [Reviewed in (Patel et al., 2013)]. Bone-marrow-derived as 
well as placental MSCs are currently being tested and considered in clinical 
trials for treating patients with PAH, ALI, IPF, COPD/emphysema and asthma 
[www.clinicaltrials.gov and reviewed in (Trounson et al., 2011)]. 
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Interestingly, non-bone marrow-derived (or resident) MSCs were reported in 
almost all postnatal organs and tissues (Da Silva Meirelles et al., 2006). It is 
believed that these cells are involved in normal as well as aberrant repair 
following injury. Failure of resident MSCs to promote tissue repair in 
pathological conditions is likely due to the fact that their microenvironmental 
niche is compromised (Scadden, 2006; Beers and Morrisey, 2011). These 
microenvironments influence MSC properties like lineage commitment, anti-
inflammatory properties, T-cell activation and differentiation to myofibroblasts 
[Reviewed in (Foronjy and Majka, 2012)]. 
The role of resident lung MSCs in lung fibrosis was demonstrated by Jun et al. 
The authors have shown that these cells are depleted in bleomycin-induced 
pulmonary fibrosis and administration of ex vivo-cultured resident lung MSCs 
attenuates lung fibrosis. These cells reduce the number of inflammatory cells 
in the BALF and inhibit T-cell proliferation (Jun et al., 2011). 
The reported work establishes Fgf10 as a marker for a subset of resident 
MSCs in the lung. Our finding that recombinant FGF10 acts on mesenchymal 
cells to induce/maintain the lipofibroblast phenotype suggests that pre-treating 
isolated MSCs with FGF10 prior to their administration could be of great use 
in treating advanced-stage IPF patients. 
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6. Summary 
FGF10 belongs to a family of evolutionary-conserved peptides that are 
involved in embryonic organogenesis as well as postnatal homeostasis. 
During embryonic lung development, Fgf10-expressing cells define the 
domain for directional growth of epithelial buds and thus orchestrate 
branching morphogenesis. Disruption of FGF10 signaling not only leads to 
failure in branching but also to malformation of various mesenchymal 
lineages. 
Here, we generated a knock-in mouse line that allows lineage tracing of 
Fgf10-expressing cells during development and postnatally in a time-
controlled manner. Our validation studies show that: 
 The Fgf10iCre knock-in line faithfully reports Fgf10 expression in many 
organs and tissues during embryonic development 
 
 The insertion of Cre-ERT2 cassette in exon 1 led to the deletion of 
intronic sequences that are critical for the maintenance of Fgf10 
expression over time. In spite of that, prolonged tamoxifen exposure 
enables the labeling of a considerable number of Fgf10-expressing cells 
in the postnatal lung. 
Our findings from the lineage tracing studies demonstrate that: 
 Fgf10-expressing cells are potent mesenchymal progenitors in vivo 
 
 Fgf10-expressing cells from early lung development give rise to 
parabronchial and vascular smooth muscle cells as well as 
lipofibroblasts during late development 
 
 Fgf10-expressing cells from late lung development and postnatally are 
precursors for lipofibroblasts rather than alveolar myofibroblasts 
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 During adult life, these cells represent a subpopulation of resident MSCs 
that, upon bleomycin injury, give rise to activated myofibroblasts 
 
 Recombinant FGF10 is capable of acting on mesenchymal cells to 
induce the lipofibroblast phenotype 
 
 Our findings suggest that these cells can be a potential target for 
treating lung fibrosis in humans. 
Thus, we propose a model in which Fgf10-expressing cells represent a 
population of resident mesenchymal stem cells that reside in the adult lung. 
Under homeostatic conditions, these cells give rise to lipofibroblasts. Injury to 
AEC II leads to a decrease in PTHrP/PPARγ signaling and increase in TGF-β 
and Wnt signaling, leading to their transdifferentiation to activated 
myofibroblasts (Fig. 28). 
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Figure 28. Model for the role of FGF10 in identifying early lipofibroblast 
progenitors and controlling their fate during development and disease. 
During embryonic development, Fgf10-positive cells give rise to lipofibroblasts and 
to a less extent smooth muscle cells (El Agha et al., Fgf10-positive cells represent a 
progenitor cell population during lung development and postnatally; in revision). 
Gain of function of FGF10 signaling in the mesenchyme inhibits smooth muscle 
formation (De Langhe et al., 2006) whereas loss of function of Fgf10 leads to 
decreased lipofibroblast formation (Fig. 23). TGF-β acts as a negative regulator of 
Fgf10 expression [Reviewed in (Cardoso and Lu, 2006)]. During disease, Fgf10-
expressing lipofibroblasts (αSma- Adrp+) transdifferentiate to activated 
myofibroblasts (Col1a1+ αSma+) likely due to increased TGF-β and Wnt signaling 
and decreased PTHrP/PPARγ and FGF10 signaling. The proposed therapeutic 
approach attempts to push activated myofibroblasts back to the lipofibroblast 
phenotype by PPARγ agonists and possibly FGF10. LIF: Lipofibroblasts. 
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7. Zusammenfassung 
FGF10 gehört zu einer Peptidfamilie, die im Laufe der Evolution stark 
konserviert wurde. Diese Peptide sind sowohl an der embryonalen 
Organogenese als auch an der postnatalen Homöostase beteiligt. Fgf10-
exprimierende Zellen bestimmen das zielgerichtete Wachstum der 
epithelialen Lungenknospen und definieren somit die morphogenetische 
Entwicklung der Lunge in der Embryonalperiode. Eine Unterbrechung des 
FGF10 Signalweges führt nicht nur zur fehlerhaften Entwicklung der 
Verästelung des Bronchialbaumes, sondern auch zur Malformation 
verschiedener anderer mesenchymalen Zelllinien. 
In der vorliegenden Arbeit wurde eine knock-in Mauslinie generiert, mit deren 
Hilfe Fgf10-exprimierende Zellen sowohl während der prä- als auch während 
der postnatalen Entwicklung zu einem beliebigen Zeitpunkt nachverfolgt 
werden können. Die Experimente zur Validierung ergaben folgende 
Resultate: 
 Die Fgf10iCre  knock-in Mauslinie zeigt die Fgf10 Expression während der 
Embryonalentwicklung in zahlreichen Organen und Geweben 
zuverlässig an 
 
 Die Insertion der Cre-ERT2 Kassette in das Exon 1 von Fgf10 führte zur 
Deletion derjenigen Intronsequenzen, welche für die Aufrechterhaltung 
der Fgf10 Expression von Bedeutung sind. Dennoch ist es möglich, 
mittels Zugabe von Tamoxifen über einen längeren Zeitraum hinweg 
eine erhebliche Anzahl von Fgf10-exprimierenden Zellen in der 
postnatalen Lunge zu markieren. 
Die Untersuchungen zum Lineage Tracing zeigten auf: 
 Fgf10-exprimierende Zellen sind in vivo potente mesenchymale 
Progenitorzellen 
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 Aus Fgf10-exprimierenden Zellen der frühen Phase der 
Lungenentwicklung entstehen im Laufe der späten Lungenentwicklung 
parabronchiale und vaskuläre glatte Muskelzellen sowie Lipofibroblasten 
 
 Postnatal und während der Spätphase der Lungenentwicklung fungieren 
Fgf10-exprimierende Zellen als Progenitorzellen für Lipofibroblasten. 
Ihre Transdifferenzierung zu Alveolar-Myofibroblasten wurde nicht 
beobachtet 
 
 In der adulten Phase stellen Fgf10-exprimierende Zellen eine 
Unterpopulation residenter mesenchymaler Stammzellen (MSC) dar, 
welche sich bei Schädigung durch Bleomycin zu aktivierten 
Myofibroblasten entwickeln 
 
 Rekombinantes FGF10 ist in der Lage, in mesenchymalen Zellen einen 
Phänotypus der Lipofibroblasten zu induzieren 
 
 Die erzielten Ergebnisse deuten darauf hin, dass Fgf10-exprimierende 
Zellen einen potentiellen therapeutischen Ansatz für die Behandlung der 
Fibrose beim Menschen darstellen können. 
Daher wird ein Modell vorgeschlagen, bei dem Fgf10-exprimierende Zellen in 
der adulten Lunge eine Zellpopulation von residenten mesenchymalen 
Stammzellen repräsentieren. Unter homöostatischen Bedingungen entwickeln 
sich aus dieser Zellpopulation Lipofibroblasten. Eine Schädigung von Typ II 
Alveolarzellen führt zur Verminderung des PTHrP/PPARγ- und einer 
Zunahme der TGF-ß und Wnt Signalwege, wodurch sie zu aktivierten 
Myofibroblasten transdifferenzieren (Abb. 28). 
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Abbildung 28. Bedeutung von FGF10 zur Identifizierung früher 
Lipofibroblasten-Progenitorzellen und dessen Einfluss auf physiologische 
und krankhafte Prozesse. 
Aus Fgf10-positiven Zellen entstehen im Laufe der embryonalen Entwicklung 
Lipofibroblasten und - in geringem Umfang - glatte Muskelzellen (El Agha et al., 
Fgf10-positive cells represent a progenitor cell population during lung development 
and postnatally; in Überarbeitung). Eine Aktivierung der FGF10 Signalwege (Gain-
of-function) im Mesenchym inhibiert die Entwicklung glatter Muskelzellen (De 
Langhe et al., 2006), während ein Verlust von Fgf10 zu einer reduzierten 
Entwicklung von Lipofibroblasten führt (Abb. 23). TGF-ß fungiert als negativer 
Regulator der Fgf10 Expression [Reviewed in (Cardoso and Lu, 2006)]. In 
krankhaften Prozessen transdifferenzieren Fgf10-exprimierende Lipofibroblasten 
(αSma- Adrp+) zu aktivierten Myofibroblasten (Col1a1+ αSma+). Es wird vermutet, 
dass dies einerseits auf eine zunehmende Aktivierung der TGF-ß und Wnt 
Signalwege zurückzuführen ist und andererseits auf eine Verminderung der 
PTHrP/PPARγ und FGF10 Signalwege. Die Rückbildung von aktivierten 
Myofibroblasten zu Lipofibroblast-phänotypischen Zellen mittels Anwendung von 
PPARγ Agonisten und möglicherweise FGF10 wäre ein potentieller therapeutischer 
Ansatz. LIF: Lipofibroblasten. 
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9. Supplementary Material 
Table S1. Clusters of differentiation and their functions in mice as described 
in the Protein Knowledgebase (UniProtKB, www.uniprot.org). 
Abbreviations: BM: Bone marrow; EpCAM: Epithelial cell adhesion molecule; ECM: 
Extracellular matrix; ES cell: Embryonic stem cell; PDGFRα: Platelet-derived 
growth factor receptor alpha; PECAM-1: Platelet/endothelial cell adhesion molecule 
1; VCAM-1: Vascular cell adhesion molecule 1. 
 
Name Protein name Function(s) 
CD24 Signal transducer CD24 
Putative: Early thymocyte 
development 
CD29 Integrin beta-1 Receptor for ECM proteins 
CD31 PECAM-1 Leukocyte transendothelial migration 
CD34 
Hematopoietic progenitor 
cell antigen CD34 
Putative: Attachment of stem cells to 
BM-ECM or directly to stromal cells 
CD44 ECM receptor III Putative: Involved in matrix adhesion 
CD45 
Receptor-type tyrosine 
protein phosphatase C or 
leukocyte common antigen 
T cell activation 
CD49f Integrin alpha-6 
Receptor for laminin 
Attachment of epithelial cells to 
basement membrane 
CD90 
THY-1 membrane 
glycoprotein 
Putative: Cell-cell adhesion 
CD104 Integrin beta-4 
Receptor for laminin 
Critical structural role in the 
hemidesmosomes of epithelial cells 
CD106 VCAM-1 Cell-cell recognition 
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Leukocyte-endothelial cell adhesion 
CD117 
Mast/stem cell growth 
factor receptor Kit or c-Kit 
Regulation of cell survival and 
proliferation, hematopoiesis and 
stem cell maintenance 
CD140a PDGFRα 
Regulation of embryonic 
development, cell proliferation and 
cell survival 
CD326  EpCAM 
Putative: An immunological barrier 
for mucosal infection in the intestine. 
ES cell proliferation and 
differentiation 
 
Table S2. Primers and probes used for qPCR and RT-PCR. 
m: mouse; h: human. 
 
Genes 
 
                          Primers UPL probes 
Taqman® assay 
Cre 
Fwd 5’-GTTTTGCCGGGTCAGAAAA-3’ 
87 
Rev 5’-GGCGCGAGTTGATAGCTG-3’ 
mFgf10 
Fwd 5’-ATGACTGTTGACATCAGACTCCTT-3’ 
63 
Rev 5’-CACTGTTCAGCCTTTTGAGGA-3’ 
mβ-actin 
Fwd 5’-TGACAGGATGCAGAAGGAGA-3’ 
106 
Rev 5’-GCGTCAGGAGGAGCAATG-3’ 
SYBR® Green assay or RT-PCR 
mAdrp 
Fwd 5’-CCTCAGCTCTCCTGTTAGGC-3’ 
- 
Rev 5’-CACTACTGCTGCTGCCATTT-3’ 
mCebpb Fwd 5'-TGATGCAATCCGGATCAA-3’ - 
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Rev 5'-CACGTGTGTTGCGTCAGTC-3’ 
mFgf10 
Fwd 5’-ATGACTGTTGACATCAGACTCCTT-3’ 
- 
Rev 5’-CACTGTTCAGCCTTTTGAGGA-3’ 
mFgfr1b 
Fwd 5’-CCACAGGTCTGGTGACAGTGA-3’ 
- 
Rev 5’-CGGGAATTAATAGCTCGGATG-3’ 
mFgfr1c 
Fwd 5’-TCTGGCCTCTACGCTTGC-3’ 
- 
Rev 5’-CTTCCGAGGATGGGAGTG-3’ 
mFgfr2b 
Fwd 5’-CCCTACCTCAAGGTCCTGAA-3’ 
- 
Rev 5’-CATCCATCTCCGTCACATTG-3’ 
mFgfr2c 
Fwd 5’-TGCATGGTTGACAGTTCTGC-3’ 
- 
Rev 5’-TGCAGGCGATTAAGAAGACC-3’ 
mFlk1 
Fwd 5’-GGGGTATGGAGACGAGCTG-3’ 
- 
Rev 5’-GCACAGATCTGACTAAATTGCTG-3’ 
mHprt 
Fwd 5’-CCTAAGATGAGCGCAAGTTGAA-3’ 
- 
Rev 5’-CCACAGGACTAGAACACCTGCTAA-3’ 
mLipase 
Fwd 5’-GCGCTGGAGGAGTGTTTTT-3’ 
- 
Rev 5’-CCGCTCTCCAGTTGAACC-3’ 
mPparg 
Fwd 5’-GAAAGACAACGGACAAATCACC-3’ 
- 
Rev 5’-GGGGGTGATATGTTTGAACTTG-3’ 
RFP 
Fwd 5’-AAGGGCGAGATCAAGATGAG-3’ 
- 
Rev 5’-GACCTCGGCGTCGTAGTG-3’ 
mSftpc 
Fwd 5’-GGTCCTGATGGAGAGTCCAC-3’ 
- 
Rev 5’-GATGAGAAGGCGTTTGAGGT-3’ 
mZfp423 
Fwd 5’-GCGATCGGTGAAAGTTGAAG-3’ 
- 
Rev 5’-TCTCCTTCCAGGCCTCCT-3’ 
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mαSma 
Fwd 5’-ACTCTCTTCCAGCCATCTTTCA-3’ 
- 
Rev 5’-ATAGGTGGTTTCGTGGATGC-3’ 
mβ-actin 
Fwd 5’-TGACAGGATGCAGAAGGAGA-3’ 
- 
Rev 5’-GCGTCAGGAGGAGCAATG-3’ 
hCEBPa 
Fwd 5'-GACATCAGCGCCTACATCG-3' 
- 
Rev 5'-GGCTGTGCTGGAACAGGT-3' 
hLipase 
Fwd 5'-GTGGCCGAGAGTGAGAACA-3' 
- 
Rev 5'-GGAAGGAGTAGGTCTTATTTGTGG-3' 
hPBGD 
Fwd 5'-TGTCTGGTAACGGCAATGCG-3' 
- 
Rev 5'-CCCACGCGAATCACTCTCAT-3' 
hPPARg 
Fwd 5'-TTGCTGTCATTATTCTCAGTGGA-3' 
- 
Rev 5'-GAGGACTCAGGGTGGTTCAG-3' 
hResistin 
Fwd 5'-TGCAGGATGAAAGCTCTCTGT-3' 
- 
Rev 5'-GGGTCTTGCTAGACACCAACA-3' 
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Figure S1. Fgf10-expressing cells from E11.5 do not stain for hematopoietic, 
endothelial or neuronal markers at E18.5. 
Immunofluorescence staining for CD45 (A), CD31 (B) and β-III Tubulin (C) on 
E18.5 Fgf10iCre/+; Tomatoflox/+ lungs. High magnification images for the areas in the 
boxes are shown in (A'), (B') and (C') respectively. Scale bar: 25 µm. 
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Figure S2. Fgf10-expressing cells from E15.5 do not stain for hematopoietic, 
endothelial or neuronal markers at E18.5. 
Immunofluorescence staining for CD45 (A), CD31 (B) and β-III Tubulin (C) on 
E18.5 Fgf10iCre/+; Tomatoflox/+ lungs. High magnification images for the areas in the 
boxes are shown in (A'), (B') and (C') respectively. Scale bar: 25 µm. 
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